drug1_db stringlengths 7 7 | drug2_db stringlengths 7 7 | drug1_id int64 0 1.69k | drug2_id int64 0 1.69k | drug_pair listlengths 2 2 | drug1_name stringlengths 4 85 | drug2_name stringlengths 4 85 | drug1_desc stringlengths 27 1.09k | drug2_desc stringlengths 27 6.14k | label stringclasses 3
values | label_idx int64 0 2 | all_paths listlengths 1 10 | all_paths_str listlengths 1 10 | path_str stringlengths 0 3.57k |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
DB00618 | DB00903 | 1,572 | 1,680 | [
"DDInter498",
"DDInter686"
] | Demeclocycline | Etacrynic acid | A tetracycline analog having a 7-chloro and a 6-methyl. Because it is excreted more slowly than tetracycline, it maintains effective blood levels for longer periods of time. | A compound that inhibits symport of sodium, potassium, and chloride primarily in the ascending limb of Henle, but also in the proximal and distal tubules. This pharmacological action results in excretion of these ions, increased urinary output, and reduction in extracellular fluid. This compound has been classified as ... | Minor | 0 | [
[
[
1572,
23,
1680
]
],
[
[
1572,
1,
1545
],
[
1545,
23,
1680
]
],
[
[
1572,
1,
1669
],
[
1669,
62,
1680
]
],
[
[
1572,
40,
964
],
[
964,
... | [
[
[
"Demeclocycline",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Etacrynic acid"
]
],
[
[
"Demeclocycline",
"{u} (Compound) resembles {v} (Compound)",
"Oxytetracycline"
],
[
"Oxytetracycline",
"{u}... | Demeclocycline (Compound) resembles Oxytetracycline (Compound) and Oxytetracycline may cause a minor interaction that can limit clinical effects when taken with Etacrynic acid
Demeclocycline (Compound) resembles Minocycline (Compound) and Minocycline may cause a minor interaction that can limit clinical effects when ta... |
DB00204 | DB04868 | 228 | 478 | [
"DDInter580",
"DDInter1293"
] | Dofetilide | Nilotinib | Dofetilide is a class III antiarrhythmic agent that is approved by the Food and Drug Administration (FDA) for the maintenance of sinus rhythm in individuals prone to the formation of atrial fibrillation and flutter, and for the chemical cardioversion to sinus rhythm from atrial fibrillation and flutter. | Nilotinib, also known as AMN107, is a tyrosine kinase inhibitor under investigation as a possible treatment for chronic myelogenous leukemia (CML). A Phase I clinical trial in 2006 showed that this drug was relatively safe and offered significant therapeutic benefits in cases of CML which were found to be resistant to ... | Major | 2 | [
[
[
228,
25,
478
]
],
[
[
228,
6,
8374
],
[
8374,
45,
478
]
],
[
[
228,
18,
4930
],
[
4930,
57,
478
]
],
[
[
228,
21,
28963
],
[
28963,
... | [
[
[
"Dofetilide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Nilotinib"
]
],
[
[
"Dofetilide",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
"Nilotini... | Dofetilide (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Nilotinib (Compound)
Dofetilide (Compound) downregulates DLD (Gene) and DLD (Gene) is downregulated by Nilotinib (Compound)
Dofetilide (Compound) causes Anxiety (Side Effect) and Anxiety (Side Effect) is caused by Nilotinib (Compound)
Dofetilide ma... |
DB00486 | DB09034 | 1,614 | 1,313 | [
"DDInter1253",
"DDInter1733"
] | Nabilone | Suvorexant | Nabilone (marketed as Cesamet) is a synthetic form of delta-9-tetrahydrocannabinol (Δ⁹-THC), the primary psychoactive component of cannabis (marijuana). Although structurally distinct from THC, nabilone mimics THC's structure and pharmacological activity through weak partial agonist activity at Cannabinoid-1 (CB1R) and... | Suvorexant is a selective dual antagonist of orexin receptors OX1R and OX2R that promotes sleep by reducing wakefulness and arousal. It has been approved for the treatment of insomnia. | Moderate | 1 | [
[
[
1614,
24,
1313
]
],
[
[
1614,
24,
649
],
[
649,
24,
1313
]
],
[
[
1614,
40,
530
],
[
530,
24,
1313
]
],
[
[
1614,
63,
701
],
[
701,
... | [
[
[
"Nabilone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Suvorexant"
]
],
[
[
"Nabilone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clofedanol"
],
[
... | Nabilone may cause a moderate interaction that could exacerbate diseases when taken with Clofedanol and Clofedanol may cause a moderate interaction that could exacerbate diseases when taken with Suvorexant
Nabilone (Compound) resembles Dronabinol (Compound) and Dronabinol may cause a moderate interaction that could exa... |
DB00108 | DB12498 | 1,066 | 76 | [
"DDInter1268",
"DDInter1238"
] | Natalizumab | Mogamulizumab | Natalizumab is a recombinant humanized IgG4κ monoclonal antibody that binds to α4-integrin. While natalizumab was originally approved by the FDA to treat multiple sclerosis in 2004, it was withdrawn from the market following multiple reports of fatal progressive multifocal leukoencephalopathy (PML). In 2006, the FDA re... | Mogamulizumab is a humanized monoclonal antibody (mAb) directed against CC chemokine receptor 4 (CCR4) for the treatment of Mycosis Fungoides (MF) and Sézary Syndrome (SS), the most common subtypes of cutaneous T-cell lymphoma. Cutaneous T-cell lymphomas occur when certain white blood cells, called T cells, become canc... | Major | 2 | [
[
[
1066,
25,
76
]
],
[
[
1066,
23,
1461
],
[
1461,
23,
76
]
],
[
[
1066,
25,
1531
],
[
1531,
24,
76
]
],
[
[
1066,
24,
496
],
[
496,
... | [
[
[
"Natalizumab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Mogamulizumab"
]
],
[
[
"Natalizumab",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Vitamin E"
],
[
"Vitamin ... | Natalizumab may cause a minor interaction that can limit clinical effects when taken with Vitamin E and Vitamin E may cause a minor interaction that can limit clinical effects when taken with Mogamulizumab
Natalizumab may lead to a major life threatening interaction when taken with Canakinumab and Canakinumab may cause... |
DB00333 | DB00357 | 576 | 1,051 | [
"DDInter1166",
"DDInter71"
] | Methadone | Aminoglutethimide | Methadone is a potent synthetic analgesic that works as a full µ-opioid receptor (MOR) agonist and N-methyl-d-aspartate (NMDA) receptor antagonist. As a full MOR agonist, methadone mimics the natural effects of the body's opioids, endorphins, and enkephalins through the release of neurotransmitters involved in pain tra... | An aromatase inhibitor that produces a state of "medical" adrenalectomy by blocking the production of adrenal steroids. It also blocks the conversion of androgens to estrogens. Aminoglutethimide has been used in the treatment of advanced breast and prostate cancer. It was formerly used for its weak anticonvulsant prope... | Major | 2 | [
[
[
576,
25,
1051
]
],
[
[
576,
6,
10450
],
[
10450,
45,
1051
]
],
[
[
576,
21,
28681
],
[
28681,
60,
1051
]
],
[
[
576,
63,
1101
],
[
110... | [
[
[
"Methadone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Aminoglutethimide"
]
],
[
[
"Methadone",
"{u} (Compound) binds {v} (Gene)",
"CYP19A1"
],
[
"CYP19A1",
"{u} (Gene) is bound by {v} (Compound)",
"... | Methadone (Compound) binds CYP19A1 (Gene) and CYP19A1 (Gene) is bound by Aminoglutethimide (Compound)
Methadone (Compound) causes Hypersensitivity (Side Effect) and Hypersensitivity (Side Effect) is caused by Aminoglutethimide (Compound)
Methadone may cause a moderate interaction that could exacerbate diseases when tak... |
DB00512 | DB00533 | 91 | 1,416 | [
"DDInter1916",
"DDInter1613"
] | Vancomycin | Rofecoxib | Antibacterial obtained from Streptomyces orientalis. It is a glycopeptide related to ristocetin that inhibits bacterial cell wall assembly and is toxic to kidneys and the inner ear. As of January 29 2018, CutisPharma's Firvanq is the only FDA approved vancomycin oral liquid treatment option available for the the treatm... | Rofecoxib is used for the treatment of osteoarthritis, rheumatoid arthritis, acute pain in adults, and primary dysmenorrhea, as well as acute treatment of migraine attacks with or without auras. Rofecoxib is a solid. This compound belongs to the stilbenes. These are organic compounds containing a 1,2-diphenylethylene m... | Moderate | 1 | [
[
[
91,
24,
1416
]
],
[
[
91,
24,
1132
],
[
1132,
63,
1416
]
],
[
[
91,
63,
1645
],
[
1645,
24,
1416
]
],
[
[
91,
24,
1555
],
[
1555,
... | [
[
[
"Vancomycin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rofecoxib"
]
],
[
[
"Vancomycin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Gentamicin"
],
[
... | Vancomycin may cause a moderate interaction that could exacerbate diseases when taken with Gentamicin and Gentamicin may cause a moderate interaction that could exacerbate diseases when taken with Rofecoxib
Vancomycin may cause a moderate interaction that could exacerbate diseases when taken with Metformin and Metformi... |
DB00357 | DB11799 | 1,051 | 627 | [
"DDInter71",
"DDInter205"
] | Aminoglutethimide | Bictegravir | An aromatase inhibitor that produces a state of "medical" adrenalectomy by blocking the production of adrenal steroids. It also blocks the conversion of androgens to estrogens. Aminoglutethimide has been used in the treatment of advanced breast and prostate cancer. It was formerly used for its weak anticonvulsant prope... | Bictegravir is a recently approved investigational drug that has been used in trials studying the treatment of HIV-1 and HIV-2 infection. It has been approved for HIV-1 monotherapy combined with 2 other antiretrovirals in a single tablet. | Moderate | 1 | [
[
[
1051,
24,
627
]
],
[
[
1051,
24,
1362
],
[
1362,
24,
627
]
],
[
[
1051,
24,
466
],
[
466,
63,
627
]
],
[
[
1051,
23,
1130
],
[
1130,
... | [
[
[
"Aminoglutethimide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bictegravir"
]
],
[
[
"Aminoglutethimide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Olaparib"
... | Aminoglutethimide may cause a moderate interaction that could exacerbate diseases when taken with Olaparib and Olaparib may cause a moderate interaction that could exacerbate diseases when taken with Bictegravir
Aminoglutethimide may cause a moderate interaction that could exacerbate diseases when taken with Darolutami... |
DB00078 | DB01125 | 1,172 | 279 | [
"DDInter898",
"DDInter98"
] | Ibritumomab tiuxetan | Anisindione | Indium or yttrium conjugated murine IgG1 kappa monoclonal antibody directed against the CD20 antigen, which is found on the surface of normal and malignant B lymphocytes. Ibritumomab is produced in Chinese hamster ovary cells and is composed of two murine gamma 1 heavy chains of 445 amino acids each and two kappa light... | Anisindione is a synthetic anticoagulant and an indanedione derivative. Its anticoagulant action is mediated through the inhibition of the vitamin K-mediated gamma-carboxylation of precursor proteins that are critical in forming the formation of active procoagulation factors II, VII, IX, and X, as well as the anticoagu... | Major | 2 | [
[
[
1172,
25,
279
]
],
[
[
1172,
24,
557
],
[
557,
63,
279
]
],
[
[
1172,
24,
222
],
[
222,
24,
279
]
],
[
[
1172,
25,
1317
],
[
1317,
... | [
[
[
"Ibritumomab tiuxetan",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Anisindione"
]
],
[
[
"Ibritumomab tiuxetan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Deoxycholic acid"
... | Ibritumomab tiuxetan may cause a moderate interaction that could exacerbate diseases when taken with Deoxycholic acid and Deoxycholic acid may cause a moderate interaction that could exacerbate diseases when taken with Anisindione
Ibritumomab tiuxetan may cause a moderate interaction that could exacerbate diseases when... |
DB00261 | DB11110 | 702 | 603 | [
"DDInter93",
"DDInter1115"
] | Anagrelide | Magnesium citrate | Anagrelide is a platelet-reducing agent used to lower dangerously elevated platelet levels (i.e. to treat thrombocythemia) in patients with myeloproliferative neoplasms. It is an oral imidazoquinazoline that was first approved for use in the US in 1997. It appears to carry a better response rate than other thrombocythe... | Magnesium citrate is a low volume and osmotic cathartic agent. The cathartic action works primarily through the high osmolarity of the solution which draws large amounts of fluid into space where is used. Magnesium citrate is considered by the FDA as an approved inactive ingredient for approved drug products under the ... | Moderate | 1 | [
[
[
702,
24,
603
]
],
[
[
702,
25,
57
],
[
57,
24,
603
]
],
[
[
702,
25,
484
],
[
484,
63,
603
]
],
[
[
702,
24,
477
],
[
477,
24,
... | [
[
[
"Anagrelide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Magnesium citrate"
]
],
[
[
"Anagrelide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Arsenic trioxide"
],
[
... | Anagrelide may lead to a major life threatening interaction when taken with Arsenic trioxide and Arsenic trioxide may cause a moderate interaction that could exacerbate diseases when taken with Magnesium citrate
Anagrelide may lead to a major life threatening interaction when taken with Entrectinib and Entrectinib may ... |
DB00539 | DB12825 | 11 | 1,375 | [
"DDInter1837",
"DDInter1032"
] | Toremifene | Lefamulin | Toremifene is a selective estrogen receptor modulator (SERM) and a nonsteroidal antiestrogen used to treat estrogen receptor positive breast cancer. Like [tamoxifen], toremifene is part of the first-generation triphenylethylene derivative chemical class of SERMs. Toremifene possesses tissue-specific actions: it has est... | Lefamulin is a pleuromutilin antibiotic used for the treatment of bacterial community-acquired pneumonia. A pleuromotilin is a more recently developed type of antibiotic that is derived from the fungus, Pleurotus mutilus. Lefamulin is available in intravenous and oral preparations and was granted FDA approval in August... | Major | 2 | [
[
[
11,
25,
1375
]
],
[
[
11,
23,
112
],
[
112,
23,
1375
]
],
[
[
11,
24,
159
],
[
159,
63,
1375
]
],
[
[
11,
63,
1101
],
[
1101,
24... | [
[
[
"Toremifene",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Lefamulin"
]
],
[
[
"Toremifene",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[
"Metronidaz... | Toremifene may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Lefamulin
Toremifene may cause a moderate interaction that could exacerbate diseases when taken with Larotrectinib and La... |
DB00791 | DB09074 | 132 | 1,362 | [
"DDInter1902",
"DDInter1327"
] | Uracil mustard | Olaparib | Nitrogen mustard derivative of uracil. It is a alkylating antineoplastic agent that is used in lymphatic malignancies, and causes mainly gastrointestinal and bone marrow damage. | Olaparib is a selective and potent inhibitor of poly (ADP-ribose) polymerase (PARP) enzymes, PARP1 and PARP2.[L41100, L40908, L43792] PARP inhibitors represent a novel class of anti-cancer therapy and they work by taking advantage of a defect in DNA repair in cancer cells with BRCA mutations and inducing cell death. Ol... | Moderate | 1 | [
[
[
132,
24,
1362
]
],
[
[
132,
24,
1683
],
[
1683,
24,
1362
]
],
[
[
132,
63,
139
],
[
139,
24,
1362
]
],
[
[
132,
24,
151
],
[
151,
... | [
[
[
"Uracil mustard",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Olaparib"
]
],
[
[
"Uracil mustard",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ustekinumab"
],
... | Uracil mustard may cause a moderate interaction that could exacerbate diseases when taken with Ustekinumab and Ustekinumab may cause a moderate interaction that could exacerbate diseases when taken with Olaparib
Uracil mustard may cause a moderate interaction that could exacerbate diseases when taken with Zidovudine an... |
DB00845 | DB01268 | 1,490 | 1,151 | [
"DDInter406",
"DDInter1731"
] | Clofazimine | Sunitinib | Clofazimine is a highly lipophilic antimicrobial riminophenazine dye used in combination with other agents, such as [dapsone], for the treatment of leprosy. It was originally described in 1957 and was the prototypical riminophenazine dye - a bright-red dye that, in its clinical use, results in long-lasting discoloratio... | Sunitinib is a small-molecule multi-targeted receptor tyrosine kinase (RTK) inhibitor. On January 26, 2006, the agent was formally approved by the US FDA for the indications of treating renal cell carcinoma (RCC) and imatinib-resistant gastrointestinal stromal tumor (GIST). For these purposes, sunitinib is generally av... | Moderate | 1 | [
[
[
1490,
24,
1151
]
],
[
[
1490,
6,
4973
],
[
4973,
45,
1151
]
],
[
[
1490,
7,
6717
],
[
6717,
46,
1151
]
],
[
[
1490,
21,
29209
],
[
292... | [
[
[
"Clofazimine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sunitinib"
]
],
[
[
"Clofazimine",
"{u} (Compound) binds {v} (Gene)",
"ABCB1"
],
[
"ABCB1",
"{u} (Gene) is bound by {v} (Compound)",
... | Clofazimine (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is bound by Sunitinib (Compound)
Clofazimine (Compound) upregulates HERPUD1 (Gene) and HERPUD1 (Gene) is upregulated by Sunitinib (Compound)
Clofazimine (Compound) causes Anorexia (Side Effect) and Anorexia (Side Effect) is caused by Sunitinib (Compound)
Clofaz... |
DB00196 | DB00404 | 600 | 523 | [
"DDInter743",
"DDInter54"
] | Fluconazole | Alprazolam | Fluconazole, commonly known as _Diflucan_, is an antifungal drug used for the treatment of both systemic and superficial fungal infections in a variety of tissues. It was initially approved by the FDA in 1990. This drug is an _azole_ antifungal, in the same drug family as [ketoconazole] and [itraconazole]. Fluconazole ... | Alprazolam is a triazolobenzodiazepine indicated for the treatment of anxiety and panic disorders.[L34783, L34788] It is mainly metabolized by CYP3As and so is contraindicated with CYP3A inhibitors like ketoconazole and itraconazole.[L34783, L34788] Benzodiazepine treatment should be stopped gradually by tapering down ... | Major | 2 | [
[
[
600,
25,
523
]
],
[
[
600,
25,
1382
],
[
1382,
1,
523
]
],
[
[
600,
24,
902
],
[
902,
40,
523
]
],
[
[
600,
6,
6799
],
[
6799,
4... | [
[
[
"Fluconazole",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Alprazolam"
]
],
[
[
"Fluconazole",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Midazolam"
],
[
"Midazolam",
"{u} (... | Fluconazole may lead to a major life threatening interaction when taken with Midazolam and Midazolam (Compound) resembles Alprazolam (Compound)
Fluconazole may cause a moderate interaction that could exacerbate diseases when taken with Clobazam and Clobazam (Compound) resembles Alprazolam (Compound)
Fluconazole (Compou... |
DB00668 | DB00816 | 874 | 1,674 | [
"DDInter652",
"DDInter1346"
] | Epinephrine | Orciprenaline | Epinephrine, also known as _adrenaline_, is a hormone and neurotransmitter and produced by the adrenal glands that can also be used as a drug due to its various important functions. Though it has long been used in the treatment of hypersensitivity reactions, epinephrine in the auto-injector form (EpiPen) has been avail... | A beta-adrenergic agonist used in the treatment of asthma and bronchospasms. [PubChem] | Moderate | 1 | [
[
[
874,
24,
1674
]
],
[
[
874,
40,
1636
],
[
1636,
24,
1674
]
],
[
[
874,
40,
693
],
[
693,
40,
1674
]
],
[
[
874,
40,
454
],
[
454,
... | [
[
[
"Epinephrine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Orciprenaline"
]
],
[
[
"Epinephrine",
"{u} (Compound) resembles {v} (Compound)",
"Phenylephrine"
],
[
"Phenylephrine",
"{u} may caus... | Epinephrine (Compound) resembles Phenylephrine (Compound) and Phenylephrine may cause a moderate interaction that could exacerbate diseases when taken with Orciprenaline
Epinephrine (Compound) resembles Isoetharine (Compound) and Isoetharine (Compound) resembles Orciprenaline (Compound)
Epinephrine (Compound) resembles... |
DB00477 | DB00804 | 216 | 1,507 | [
"DDInter363",
"DDInter543"
] | Chlorpromazine | Dicyclomine | The prototypical phenothiazine antipsychotic drug. Like the other drugs in this class, chlorpromazine's antipsychotic actions are thought to be due to long-term adaptation by the brain to blocking dopamine receptors. Chlorpromazine has several other actions and therapeutic uses, including as an antiemetic and in the tr... | Dicyclomine is a muscarinic M1, M3, and M2 receptor antagonist as well as a non-competitive inhibitor of histamine and bradykinin used to treat spasms of the intestines seen in functional bowel disorder and irritable bowel syndrome.[A6556,A182555,A234659,L7967] Though it is commonly prescribed, its recommendation may h... | Moderate | 1 | [
[
[
216,
24,
1507
]
],
[
[
216,
6,
2720
],
[
2720,
45,
1507
]
],
[
[
216,
21,
28786
],
[
28786,
60,
1507
]
],
[
[
216,
24,
1021
],
[
1021,... | [
[
[
"Chlorpromazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dicyclomine"
]
],
[
[
"Chlorpromazine",
"{u} (Compound) binds {v} (Gene)",
"CHRM3"
],
[
"CHRM3",
"{u} (Gene) is bound by {v} (Comp... | Chlorpromazine (Compound) binds CHRM3 (Gene) and CHRM3 (Gene) is bound by Dicyclomine (Compound)
Chlorpromazine (Compound) causes Urinary retention (Side Effect) and Urinary retention (Side Effect) is caused by Dicyclomine (Compound)
Chlorpromazine may cause a moderate interaction that could exacerbate diseases when ta... |
DB00186 | DB01377 | 905 | 1,283 | [
"DDInter1092",
"DDInter1119"
] | Lorazepam | Magnesium oxide | Lorazepam is a short-acting and rapidly cleared benzodiazepine used commonly as a sedative and anxiolytic. It was developed by DJ Richards, presented and marketed initially by Wyeth Pharmaceuticals in the USA in 1977. The first historic FDA label approval is reported in 1985 by the company Mutual Pharm. | Magnesium oxide is an inorganic compound that occurs in nature as the mineral periclase. In aqueous media combines quickly with water to form magnesium hydroxide. It is used as an antacid and mild laxative and has many nonmedicinal uses. | Minor | 0 | [
[
[
905,
23,
1283
]
],
[
[
905,
40,
1174
],
[
1174,
23,
1283
]
],
[
[
905,
24,
104
],
[
104,
23,
1283
]
],
[
[
905,
40,
481
],
[
481,
... | [
[
[
"Lorazepam",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Magnesium oxide"
]
],
[
[
"Lorazepam",
"{u} (Compound) resembles {v} (Compound)",
"Temazepam"
],
[
"Temazepam",
"{u} may cause a minor in... | Lorazepam (Compound) resembles Temazepam (Compound) and Temazepam may cause a minor interaction that can limit clinical effects when taken with Magnesium oxide
Lorazepam may cause a moderate interaction that could exacerbate diseases when taken with Methdilazine and Methdilazine may cause a minor interaction that can l... |
DB00590 | DB01285 | 1,433 | 708 | [
"DDInter592",
"DDInter445"
] | Doxazosin | Corticotropin | Doxazosin is an alpha-1 antagonist used for the treatment of benign prostatic hypertrophy (BPH) symptoms and hypertension. Other members of this drug class include [Prazosin], [Terazosin], [Tamsulosin], and [Alfuzosin]. Because of its long-lasting effects, doxazosin can be administered once a day. It is marketed by Pfi... | Corticotropin (ACTH or adrenocorticotropic hormone) is a polypeptide hormone produced and secreted by the pituitary gland. It is an important player in the hypothalamic-pituitary-adrenal axis. | Moderate | 1 | [
[
[
1433,
24,
708
]
],
[
[
1433,
1,
1205
],
[
1205,
24,
708
]
],
[
[
1433,
24,
1450
],
[
1450,
63,
708
]
],
[
[
1433,
40,
195
],
[
195,
... | [
[
[
"Doxazosin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Corticotropin"
]
],
[
[
"Doxazosin",
"{u} (Compound) resembles {v} (Compound)",
"Prazosin"
],
[
"Prazosin",
"{u} may cause a moderate i... | Doxazosin (Compound) resembles Prazosin (Compound) and Prazosin may cause a moderate interaction that could exacerbate diseases when taken with Corticotropin
Doxazosin may cause a moderate interaction that could exacerbate diseases when taken with Empagliflozin and Empagliflozin may cause a moderate interaction that co... |
DB00619 | DB01211 | 1,419 | 609 | [
"DDInter909",
"DDInter393"
] | Imatinib | Clarithromycin | Imatinib is a small molecule kinase inhibitor that revolutionized the treatment of cancer, particularly chronic myeloid leukemia, in 2001. It was deemed a "miracle drug" due to its clinical success, as oncologist Dr. Brian noted that "complete hematologic responses were observed in 53 of 54 patients with CML treated wi... | Clarithromycin, a semisynthetic macrolide antibiotic derived from erythromycin, inhibits bacterial protein synthesis by binding to the bacterial 50S ribosomal subunit. Binding inhibits peptidyl transferase activity and interferes with amino acid translocation during the translation and protein assembly process. Clarith... | Moderate | 1 | [
[
[
1419,
24,
609
]
],
[
[
1419,
6,
4973
],
[
4973,
45,
609
]
],
[
[
1419,
7,
4333
],
[
4333,
46,
609
]
],
[
[
1419,
18,
7247
],
[
7247,
... | [
[
[
"Imatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clarithromycin"
]
],
[
[
"Imatinib",
"{u} (Compound) binds {v} (Gene)",
"ABCB1"
],
[
"ABCB1",
"{u} (Gene) is bound by {v} (Compound)",
... | Imatinib (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is bound by Clarithromycin (Compound)
Imatinib (Compound) upregulates MEF2C (Gene) and MEF2C (Gene) is upregulated by Clarithromycin (Compound)
Imatinib (Compound) downregulates NPDC1 (Gene) and NPDC1 (Gene) is downregulated by Clarithromycin (Compound)
Imatinib (... |
DB00364 | DB00960 | 417 | 887 | [
"DDInter1717",
"DDInter1471"
] | Sucralfate | Pindolol | Sucralfate is a medication that is widely used to prevent and treat a number of diseases in the gastrointestinal tract such as duodenal ulcers [FDA label], gastro-esophageal reflux disease (GERD), gastritis, peptic ulcer disease, stress ulcer, in addition to dyspepsia. It is considered a _cytoprotective agent_, protect... | Pindolol is a first generation non-selective beta blocker used in the treatment of hypertension. Early research into the use of pindolol found it had chronotropic effects, and so further investigation focused on the treatment of arrhythmia. Research into pindolol's use in the treatment of hypertension began in the earl... | Minor | 0 | [
[
[
417,
23,
887
]
],
[
[
417,
23,
819
],
[
819,
40,
887
]
],
[
[
417,
62,
88
],
[
88,
40,
887
]
],
[
[
417,
23,
1121
],
[
1121,
1,
... | [
[
[
"Sucralfate",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Pindolol"
]
],
[
[
"Sucralfate",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Acebutolol"
],
[
"A... | Sucralfate may cause a minor interaction that can limit clinical effects when taken with Acebutolol and Acebutolol (Compound) resembles Pindolol (Compound)
Sucralfate may cause a minor interaction that can limit clinical effects when taken with Metoprolol and Metoprolol (Compound) resembles Pindolol (Compound)
Sucralfa... |
DB00015 | DB10672 | 582 | 297 | [
"DDInter1585",
"DDInter417"
] | Reteplase | Clove | Human tissue plasminogen activator, purified, glycosylated, 355 residues purified from CHO cells. Retavase is considered a "third-generation" thrombolytic agent, genetically engineered to retain and delete certain portions of human tPA. Retavase is a deletion mutein of human tPA formed by deleting various amino acids p... | Clove allergenic extract is used in allergenic testing. | Minor | 0 | [
[
[
582,
23,
297
]
],
[
[
582,
25,
235
],
[
235,
62,
297
]
],
[
[
582,
24,
578
],
[
578,
23,
297
]
],
[
[
582,
25,
1564
],
[
1564,
2... | [
[
[
"Reteplase",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Clove"
]
],
[
[
"Reteplase",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Desirudin"
],
[
"Desirudin",
"{... | Reteplase may lead to a major life threatening interaction when taken with Desirudin and Desirudin may cause a minor interaction that can limit clinical effects when taken with Clove
Reteplase may cause a moderate interaction that could exacerbate diseases when taken with Ticagrelor and Ticagrelor may cause a minor int... |
DB00321 | DB01114 | 21 | 272 | [
"DDInter78",
"DDInter362"
] | Amitriptyline | Chlorpheniramine | Amitriptyline is a tricyclic antidepressant that has been used to treat depression for decades. ELAVIL, a previously approved branded product of amitriptyline, was first approved by the FDA in 1961. Amitriptyline has been investigated in the treatment of pain-related conditions, attributed to its analgesic properties. | A histamine H1 antagonist used in allergic reactions, hay fever, rhinitis, urticaria, and asthma. It has also been used in veterinary applications. One of the most widely used of the classical antihistaminics, it generally causes less drowsiness and sedation than promethazine. | Moderate | 1 | [
[
[
21,
24,
272
]
],
[
[
21,
1,
358
],
[
358,
63,
272
]
],
[
[
21,
40,
11244
],
[
11244,
1,
272
]
],
[
[
21,
1,
11296
],
[
11296,
1,... | [
[
[
"Amitriptyline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Chlorpheniramine"
]
],
[
[
"Amitriptyline",
"{u} (Compound) resembles {v} (Compound)",
"Orphenadrine"
],
[
"Orphenadrine",
"{u} may... | Amitriptyline (Compound) resembles Orphenadrine (Compound) and Orphenadrine may cause a moderate interaction that could exacerbate diseases when taken with Chlorpheniramine
Amitriptyline (Compound) resembles Pheniramine (Compound) and Pheniramine (Compound) resembles Chlorpheniramine (Compound)
Amitriptyline (Compound)... |
DB00533 | DB04932 | 1,416 | 1,564 | [
"DDInter1613",
"DDInter491"
] | Rofecoxib | Defibrotide | Rofecoxib is used for the treatment of osteoarthritis, rheumatoid arthritis, acute pain in adults, and primary dysmenorrhea, as well as acute treatment of migraine attacks with or without auras. Rofecoxib is a solid. This compound belongs to the stilbenes. These are organic compounds containing a 1,2-diphenylethylene m... | Defibrotide is the sodium salt of a mixture of single-stranded oligodeoxyribonucleotides derived from porcine mucosal DNA. It has been shown to have antithrombotic, anti-inflammatory and anti-ischemic properties (but without associated significant systemic anticoagulant effects). It is marketed under the brand names Da... | Moderate | 1 | [
[
[
1416,
24,
1564
]
],
[
[
1416,
24,
714
],
[
714,
24,
1564
]
],
[
[
1416,
63,
1061
],
[
1061,
24,
1564
]
],
[
[
1416,
24,
1347
],
[
1347... | [
[
[
"Rofecoxib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Defibrotide"
]
],
[
[
"Rofecoxib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Iloprost"
],
[
... | Rofecoxib may cause a moderate interaction that could exacerbate diseases when taken with Iloprost and Iloprost may cause a moderate interaction that could exacerbate diseases when taken with Defibrotide
Rofecoxib may cause a moderate interaction that could exacerbate diseases when taken with Treprostinil and Treprosti... |
DB00952 | DB09241 | 1,541 | 1,629 | [
"DDInter1267",
"DDInter1186"
] | Naratriptan | Methylene blue | Naratriptan is a triptan drug that is selective for the 5-hydroxytryptamine1 receptor subtype. It is typically used for the treatment of migraine headaches. | Methylene blue is an oxidation-reduction agent. The intravenous form of methylene blue is approved by the FDA for the treatment of pediatric and adult patients with acquired methemoglobinemia. Historically, it has been widely used in Africa to treat malaria, but now it disappeared when chloroquine (CQ) and other drugs ... | Major | 2 | [
[
[
1541,
25,
1629
]
],
[
[
1541,
40,
1373
],
[
1373,
25,
1629
]
],
[
[
1541,
63,
475
],
[
475,
25,
1629
]
],
[
[
1541,
25,
1039
],
[
1039... | [
[
[
"Naratriptan",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Methylene blue"
]
],
[
[
"Naratriptan",
"{u} (Compound) resembles {v} (Compound)",
"Almotriptan"
],
[
"Almotriptan",
"{u} may lead to a major life t... | Naratriptan (Compound) resembles Almotriptan (Compound) and Almotriptan may lead to a major life threatening interaction when taken with Methylene blue
Naratriptan may cause a moderate interaction that could exacerbate diseases when taken with Morphine and Morphine may lead to a major life threatening interaction when ... |
DB00434 | DB06016 | 13 | 1,508 | [
"DDInter459",
"DDInter300"
] | Cyproheptadine | Cariprazine | Cyproheptadine is a potent competitive antagonist of both serotonin and histamine receptors. It is used primarily to treat allergic symptoms, though it is perhaps more notable for its use in appetite stimulation and its off-label use in the treatment of serotonin syndrome. | Cariprazine is an atypical antipsychotic agent and a piperazine derivative that was first developed in Hungary. It works as a partial agonist at central dopamine D2, dopamine D3, and serotonin 5-HT<sub>1A</sub> receptors and as an antagonist at serotonin 5-HT<sub>2A</sub> receptors. Cariprazine has been investigated in... | Moderate | 1 | [
[
[
13,
24,
1508
]
],
[
[
13,
63,
1242
],
[
1242,
24,
1508
]
],
[
[
13,
24,
1507
],
[
1507,
24,
1508
]
],
[
[
13,
24,
849
],
[
849,
... | [
[
[
"Cyproheptadine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cariprazine"
]
],
[
[
"Cyproheptadine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cetirizine"
],... | Cyproheptadine may cause a moderate interaction that could exacerbate diseases when taken with Cetirizine and Cetirizine may cause a moderate interaction that could exacerbate diseases when taken with Cariprazine
Cyproheptadine may cause a moderate interaction that could exacerbate diseases when taken with Dicyclomine ... |
DB08903 | DB14723 | 996 | 159 | [
"DDInter170",
"DDInter1026"
] | Bedaquiline | Larotrectinib | Bedaquiline is a bactericidal antimycobacterial drug belonging to the class of diarylquinoline. The quinolinic central heterocyclic nucleus with alcohol and amine side chains is responsible for bedaquiline-mediated antimycobacterial activity. Although it is closely related to fluoroquinolones, bedaquiline does not affe... | Larotrectinib is an orally administered inhibitor of tropomyosin receptor kinase (Trk), a receptor tyrosine kinase activated by neurotrophins which is mutated in a variety of cancer cell types and plays an important role in tumor cell growth and survival. Upon administration, larotrectinib binds to Trk, thereby prevent... | Moderate | 1 | [
[
[
996,
24,
159
]
],
[
[
996,
24,
98
],
[
98,
24,
159
]
],
[
[
996,
64,
1181
],
[
1181,
24,
159
]
],
[
[
996,
63,
267
],
[
267,
24,... | [
[
[
"Bedaquiline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Larotrectinib"
]
],
[
[
"Bedaquiline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Somatrem"
],
[... | Bedaquiline may cause a moderate interaction that could exacerbate diseases when taken with Somatrem and Somatrem may cause a moderate interaction that could exacerbate diseases when taken with Larotrectinib
Bedaquiline may lead to a major life threatening interaction when taken with Terfenadine and Terfenadine may cau... |
DB00912 | DB14731 | 473 | 1,518 | [
"DDInter1581",
"DDInter1741"
] | Repaglinide | Tagraxofusp | Repaglinide is an oral antihyperglycemic agent used for the treatment of non-insulin-dependent diabetes mellitus (NIDDM). It belongs to the meglitinide class of short-acting insulin secretagogues, which act by binding to β cells of the pancreas to stimulate insulin release. Repaglinide induces an early insulin response... | Tagraxofusp is a CD123-directed cytotoxin. It is a fusion protein composed of a human interleukin-3 (IL-3) that is genetically fused to the catalytic and translocation domains of truncated diphtheria toxin (DT) produced in _Escherichia coli_.[A253762, A253887, L43702] Tagraxofusp received its first global approval by t... | Moderate | 1 | [
[
[
473,
24,
1518
]
],
[
[
473,
24,
123
],
[
123,
24,
1518
]
],
[
[
473,
63,
1324
],
[
1324,
24,
1518
]
],
[
[
473,
63,
695
],
[
695,
... | [
[
[
"Repaglinide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tagraxofusp"
]
],
[
[
"Repaglinide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Exenatide"
],
[
... | Repaglinide may cause a moderate interaction that could exacerbate diseases when taken with Exenatide and Exenatide may cause a moderate interaction that could exacerbate diseases when taken with Tagraxofusp
Repaglinide may cause a moderate interaction that could exacerbate diseases when taken with Troglitazone and Tro... |
DB01128 | DB15233 | 918 | 1,650 | [
"DDInter204",
"DDInter142"
] | Bicalutamide | Avapritinib | Bicalutamide is an oral non-steroidal anti-androgen for prostate cancer. It is comprised of a racemic mixture that is a 50:50 composition of the (R)-bicalutamide and (S)-bicalutamide enantionmers. Bicalutamide binds to the androgen receptor. | Avapritinib, or BLU-285, is a selective tyrosine kinase inhibitor of KIT and platelet derived growth factor receptor alpha indicated for the treatment of unresectable, metastatic gastrointestinal stromal tumors and advanced systemic mastocytosis.[A189339,L40363] It is one of the first medications available for the trea... | Moderate | 1 | [
[
[
918,
24,
1650
]
],
[
[
918,
24,
1478
],
[
1478,
24,
1650
]
],
[
[
918,
25,
982
],
[
982,
24,
1650
]
],
[
[
918,
63,
842
],
[
842,
... | [
[
[
"Bicalutamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Avapritinib"
]
],
[
[
"Bicalutamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ivacaftor"
],
... | Bicalutamide may cause a moderate interaction that could exacerbate diseases when taken with Ivacaftor and Ivacaftor may cause a moderate interaction that could exacerbate diseases when taken with Avapritinib
Bicalutamide may lead to a major life threatening interaction when taken with Ivosidenib and Ivosidenib may cau... |
DB00188 | DB12240 | 168 | 110 | [
"DDInter222",
"DDInter1485"
] | Bortezomib | Polatuzumab vedotin | Bortezomib is a dipeptide boronic acid derivative and proteasome inhibitor used to treat multiple myeloma and mantle cell lymphoma. The 26S proteasome is a protein complex that degrades ubiquitinated proteins in the ubiquitin-proteasome pathway: reversible inhibition of the 26S proteasome, leading to cell cycle arrest ... | Polatuzumab vedotin is a CD79b-directed antibody-drug conjugate that delivers monomethyl auristatin E (MMAE), an anti-mitotic agent, to cancer cells. The drug consists of three components - a humanized immunoglobulin G1 (IgG1) monoclonal antibody specific for human CD79b (polatuzumab), MMAE, and protease-cleavable link... | Moderate | 1 | [
[
[
168,
24,
110
]
],
[
[
168,
25,
129
],
[
129,
23,
110
]
],
[
[
168,
24,
467
],
[
467,
24,
110
]
],
[
[
168,
63,
268
],
[
268,
24,... | [
[
[
"Bortezomib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Polatuzumab vedotin"
]
],
[
[
"Bortezomib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Enzalutamide"
],
[
... | Bortezomib may lead to a major life threatening interaction when taken with Enzalutamide and Enzalutamide may cause a minor interaction that can limit clinical effects when taken with Polatuzumab vedotin
Bortezomib may cause a moderate interaction that could exacerbate diseases when taken with Simvastatin and Simvastat... |
DB00570 | DB01095 | 147 | 671 | [
"DDInter1936",
"DDInter769"
] | Vinblastine | Fluvastatin | Antitumor alkaloid isolated from Vinca rosea. (Merck, 11th ed.) | Fluvastatin is an antilipemic agent that competitively inhibits hydroxymethylglutaryl-coenzyme A (HMG-CoA) reductase. HMG-CoA reductase catalyzes the conversion of HMG-CoA to mevalonic acid, the rate-limiting step in cholesterol biosynthesis. Fluvastatin belongs to a class of medications called statins and is used to r... | Moderate | 1 | [
[
[
147,
24,
671
]
],
[
[
147,
24,
788
],
[
788,
40,
671
]
],
[
[
147,
24,
14
],
[
14,
63,
671
]
],
[
[
147,
6,
12523
],
[
12523,
45... | [
[
[
"Vinblastine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fluvastatin"
]
],
[
[
"Vinblastine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pitavastatin"
],
... | Vinblastine may cause a moderate interaction that could exacerbate diseases when taken with Pitavastatin and Pitavastatin (Compound) resembles Fluvastatin (Compound)
Vinblastine may cause a moderate interaction that could exacerbate diseases when taken with Rosuvastatin and Rosuvastatin may cause a moderate interaction... |
DB01234 | DB12674 | 1,220 | 975 | [
"DDInter513",
"DDInter1105"
] | Dexamethasone | Lurbinectedin | Dexamethasone, or MK-125, is a corticosteroid fluorinated at position 9 used to treat endocrine, rheumatic, collagen, dermatologic, allergic, ophthalmic, gastrointestinal, respiratory, hematologic, neoplastic, edematous, and other conditions. Developed in 1957, it is structurally similar to other corticosteroids like [... | Lurbinectedin is a DNA alkylating agent that has been investigated in the treatment of a variety of cancers, including mesothelioma, chronic lymphocytic leukemia (CLL), breast cancer, and small-cell lung cancer (SCLC). It is a derivative of the marine-derived agent ecteinascidin ([trabectedin]), an anticancer agent fou... | Major | 2 | [
[
[
1220,
25,
975
]
],
[
[
1220,
24,
159
],
[
159,
63,
975
]
],
[
[
1220,
24,
98
],
[
98,
24,
975
]
],
[
[
1220,
63,
147
],
[
147,
2... | [
[
[
"Dexamethasone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Lurbinectedin"
]
],
[
[
"Dexamethasone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Larotrectinib"
],
[
... | Dexamethasone may cause a moderate interaction that could exacerbate diseases when taken with Larotrectinib and Larotrectinib may cause a moderate interaction that could exacerbate diseases when taken with Lurbinectedin
Dexamethasone may cause a moderate interaction that could exacerbate diseases when taken with Somatr... |
DB00745 | DB01229 | 307 | 973 | [
"DDInter1236",
"DDInter1377"
] | Modafinil | Paclitaxel | Modafinil is a stimulant drug marketed as a 'wakefulness promoting agent' and is one of the stimulants used in the treatment of narcolepsy. Narcolepsy is caused by dysfunction of a family of wakefulness-promoting and sleep-suppressing peptides, the orexins, whose neurons are activated by modafinil. The prexin neuron ac... | Paclitaxel is a chemotherapeutic agent marketed under the brand name Taxol among others. Used as a treatment for various cancers, paclitaxel is a mitotic inhibitor that was first isolated in 1971 from the bark of the Pacific yew tree which contains endophytic fungi that synthesize paclitaxel. It is available as an intr... | Minor | 0 | [
[
[
307,
23,
973
]
],
[
[
307,
23,
310
],
[
310,
63,
973
]
],
[
[
307,
6,
7524
],
[
7524,
45,
973
]
],
[
[
307,
18,
10375
],
[
10375,
... | [
[
[
"Modafinil",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Paclitaxel"
]
],
[
[
"Modafinil",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Cabazitaxel"
],
[
"... | Modafinil may cause a minor interaction that can limit clinical effects when taken with Cabazitaxel and Cabazitaxel may cause a moderate interaction that could exacerbate diseases when taken with Paclitaxel
Modafinil (Compound) binds CYP3A5 (Gene) and CYP3A5 (Gene) is bound by Paclitaxel (Compound)
Modafinil (Compound)... |
DB01001 | DB01238 | 688 | 673 | [
"DDInter1632",
"DDInter118"
] | Salbutamol | Aripiprazole | Salbutamol is a short-acting, selective beta2-adrenergic receptor agonist used in the treatment of asthma and COPD. It is 29 times more selective for beta2 receptors than beta1 receptors giving it higher specificity for pulmonary beta receptors versus beta1-adrenergic receptors located in the heart. Salbutamol is formu... | Aripiprazole is an atypical antipsychotic orally indicated for the treatment of schizophrenia, bipolar I, major depressive disorder, irritability associated with autism, and Tourette's. It is also indicated as an injection for agitation associated with schizophrenia or bipolar mania. Aripiprazole exerts its effects thr... | Moderate | 1 | [
[
[
688,
24,
673
]
],
[
[
688,
63,
827
],
[
827,
40,
673
]
],
[
[
688,
63,
1630
],
[
1630,
1,
673
]
],
[
[
688,
6,
1704
],
[
1704,
4... | [
[
[
"Salbutamol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Aripiprazole"
]
],
[
[
"Salbutamol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Trazodone"
],
[
... | Salbutamol may cause a moderate interaction that could exacerbate diseases when taken with Trazodone and Trazodone (Compound) resembles Aripiprazole (Compound)
Salbutamol may cause a moderate interaction that could exacerbate diseases when taken with Perphenazine and Perphenazine (Compound) resembles Aripiprazole (Comp... |
DB01128 | DB12141 | 918 | 971 | [
"DDInter204",
"DDInter817"
] | Bicalutamide | Gilteritinib | Bicalutamide is an oral non-steroidal anti-androgen for prostate cancer. It is comprised of a racemic mixture that is a 50:50 composition of the (R)-bicalutamide and (S)-bicalutamide enantionmers. Bicalutamide binds to the androgen receptor. | Gilteritinib, also known as ASP2215, is a small molecule part of the FLT3 tyrosine kinase inhibitors that presented a greater selectivity and potency when compared with other agents from this group. It is a pyrazinecarboxamide derivative that showed high selectivity to FLT3 preventing the c-Kit -driven myelosuppression... | Moderate | 1 | [
[
[
918,
24,
971
]
],
[
[
918,
23,
1135
],
[
1135,
23,
971
]
],
[
[
918,
62,
1247
],
[
1247,
23,
971
]
],
[
[
918,
63,
485
],
[
485,
... | [
[
[
"Bicalutamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Gilteritinib"
]
],
[
[
"Bicalutamide",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Naloxegol"
],
[... | Bicalutamide may cause a minor interaction that can limit clinical effects when taken with Naloxegol and Naloxegol may cause a minor interaction that can limit clinical effects when taken with Gilteritinib
Bicalutamide may cause a minor interaction that can limit clinical effects when taken with Sulfamethoxazole and Su... |
DB00363 | DB09472 | 695 | 1,383 | [
"DDInter419",
"DDInter1693"
] | Clozapine | Sodium sulfate | Clozapine is a tricyclic dibenzodiazepine, classified as an atypical antipsychotic agent. Clozapine displays affinity to various neuroreceptors with a particularly low affinity to the dopamine receptors, thus breaking the mold of first-generation antipsychotics and deeming it "atypical".. This low affinity to dopamine ... | Sodium Sulfate Anhydrous is the anhydrous, sodium salt form of sulfuric acid. Sodium sulfate anhydrous disassociates in water to provide sodium ions and sulfate ions. Sodium ion is the principal cation of the extracellular fluid and plays a large part in the therapy of fluid and electrolyte disturbances. Sodium sulfate... | Major | 2 | [
[
[
695,
25,
1383
]
],
[
[
695,
24,
609
],
[
609,
24,
1383
]
],
[
[
695,
25,
1311
],
[
1311,
24,
1383
]
],
[
[
695,
64,
521
],
[
521,
... | [
[
[
"Clozapine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Sodium sulfate"
]
],
[
[
"Clozapine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clarithromycin"
],
[
"Clar... | Clozapine may cause a moderate interaction that could exacerbate diseases when taken with Clarithromycin and Clarithromycin may cause a moderate interaction that could exacerbate diseases when taken with Sodium sulfate
Clozapine may lead to a major life threatening interaction when taken with Metoclopramide and Metoclo... |
DB00432 | DB10343 | 1,083 | 962 | [
"DDInter1868",
"DDInter160"
] | Trifluridine | Bacillus calmette-guerin substrain tice live antigen | Trifluridine is a fluorinated pyrimidine nucleoside that is structurally related to [idoxuridine]. It is an active antiviral agent in ophthalmic solutions used mainly in the treatment of primary keratoconjunctivitis and recurrent epithelial keratitis due to herpes simplex virus. It displays effective antiviral activity... | Bacillus calmette-guerin substrain tice live antigen is a vaccine containing attenuated live culture preparation of the Bacillus of Calmette and Guerin (BCG) strain of *Mycobacterium bovis* for percutaneous use. It is administered to prevent the development of tuberculosis. | Major | 2 | [
[
[
1083,
25,
962
]
],
[
[
1083,
64,
1057
],
[
1057,
25,
962
]
],
[
[
1083,
24,
270
],
[
270,
64,
962
]
],
[
[
1083,
24,
1362
],
[
1362,
... | [
[
[
"Trifluridine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Bacillus calmette-guerin substrain tice live antigen"
]
],
[
[
"Trifluridine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Etanercept"... | Trifluridine may lead to a major life threatening interaction when taken with Etanercept and Etanercept may lead to a major life threatening interaction when taken with Bacillus calmette-guerin substrain tice live antigen
Trifluridine may cause a moderate interaction that could exacerbate diseases when taken with Ocrel... |
DB00009 | DB01191 | 1,271 | 1,039 | [
"DDInter56",
"DDInter518"
] | Alteplase | Dexfenfluramine | Alteplase is a recombinant tissue plasminogen activator (rt-PA) used as a thrombolytic agent. It cleaves plasminogen to form plasmin, an enzyme involved in the degradation of fibrin clots. In the absence of fibrin, the alteplase-mediated conversion of plasminogen is limited, thanks to the high affinity between alteplas... | Dexfenfluramine, also marketed under the name Redux, is a serotoninergic anorectic drug. For a fairly limited time during the middle of the nineties, the US FDA had approved it for use in managing weight loss. However, following multiple concerns about the cardiovascular side-effects of the drug, such approval was with... | Moderate | 1 | [
[
[
1271,
24,
1039
]
],
[
[
1271,
25,
1046
],
[
1046,
63,
1039
]
],
[
[
1271,
24,
578
],
[
578,
63,
1039
]
],
[
[
1271,
24,
935
],
[
935,
... | [
[
[
"Alteplase",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dexfenfluramine"
]
],
[
[
"Alteplase",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Caplacizumab"
],
[
"Capla... | Alteplase may lead to a major life threatening interaction when taken with Caplacizumab and Caplacizumab may cause a moderate interaction that could exacerbate diseases when taken with Dexfenfluramine
Alteplase may cause a moderate interaction that could exacerbate diseases when taken with Ticagrelor and Ticagrelor may... |
DB00294 | DB09046 | 1,336 | 1,094 | [
"DDInter701",
"DDInter1201"
] | Etonogestrel | Metreleptin | Etonogestrel molecule is a 3-ketodesogestrel or 19-nortestosterone which is a synthetic biologically active metabolite of progestin desogestrel. The first product including etonogestrel was developed by the Merck subsidiary Organon and FDA approved in 2001. | Metreleptin, a recombinant analog of the human hormone leptin, is an orphan drug used to treat complications of leptin deficiency in people with lipodystrophy. Lipodystrophies include a range of disorders characterized by the reduction, absence, or altered distribution of adipose tissue. Complications of lipodystrophy ... | Moderate | 1 | [
[
[
1336,
24,
1094
]
],
[
[
1336,
24,
1213
],
[
1213,
24,
1094
]
],
[
[
1336,
63,
1031
],
[
1031,
24,
1094
]
],
[
[
1336,
40,
1657
],
[
16... | [
[
[
"Etonogestrel",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Metreleptin"
]
],
[
[
"Etonogestrel",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dasatinib"
],
... | Etonogestrel may cause a moderate interaction that could exacerbate diseases when taken with Dasatinib and Dasatinib may cause a moderate interaction that could exacerbate diseases when taken with Metreleptin
Etonogestrel may cause a moderate interaction that could exacerbate diseases when taken with Theophylline and T... |
DB00344 | DB12267 | 1,302 | 1,476 | [
"DDInter1543",
"DDInter233"
] | Protriptyline | Brigatinib | Protriptyline hydrochloride is a dibenzocycloheptene-derivative tricyclic antidepressant (TCA). TCAs are structurally similar to phenothiazines. They contain a tricyclic ring system with an alkyl amine substituent on the central ring. In non-depressed individuals, protriptyline does not affect mood or arousal, but may ... | Brigatinib, originally named AP26113, is a reversible dual inhibitor of anaplastic lymphoma kinase (ALK) and epidermal growth factor receptor (EGFR). It presents selectivity against the mutant forms of EGFR compared to the wild-type. It also exhibits selectivity against 9 different Crizotinib-resistant mutants of the E... | Moderate | 1 | [
[
[
1302,
24,
1476
]
],
[
[
1302,
24,
918
],
[
918,
24,
1476
]
],
[
[
1302,
25,
1133
],
[
1133,
24,
1476
]
],
[
[
1302,
63,
1181
],
[
1181... | [
[
[
"Protriptyline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Brigatinib"
]
],
[
[
"Protriptyline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bicalutamide"
],
... | Protriptyline may cause a moderate interaction that could exacerbate diseases when taken with Bicalutamide and Bicalutamide may cause a moderate interaction that could exacerbate diseases when taken with Brigatinib
Protriptyline may lead to a major life threatening interaction when taken with Granisetron and Granisetro... |
DB00619 | DB14783 | 1,419 | 287 | [
"DDInter909",
"DDInter574"
] | Imatinib | Diroximel fumarate | Imatinib is a small molecule kinase inhibitor that revolutionized the treatment of cancer, particularly chronic myeloid leukemia, in 2001. It was deemed a "miracle drug" due to its clinical success, as oncologist Dr. Brian noted that "complete hematologic responses were observed in 53 of 54 patients with CML treated wi... | Multiple Sclerosis (MS) is a chronic, debilitating neurological disease that can lead to profound cognitive and physical symptoms, severely affecting quality of life. It is the main cause of neurological disability not caused by trauma in the young adult population of both North America and Europe. Relapsing-remitting ... | Moderate | 1 | [
[
[
1419,
24,
287
]
],
[
[
1419,
62,
1101
],
[
1101,
24,
287
]
],
[
[
1419,
63,
1560
],
[
1560,
24,
287
]
],
[
[
1419,
24,
384
],
[
384,
... | [
[
[
"Imatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Diroximel fumarate"
]
],
[
[
"Imatinib",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Bexarotene"
],
[
... | Imatinib may cause a minor interaction that can limit clinical effects when taken with Bexarotene and Bexarotene may cause a moderate interaction that could exacerbate diseases when taken with Diroximel fumarate
Imatinib may cause a moderate interaction that could exacerbate diseases when taken with Pegaspargase and Pe... |
DB00372 | DB04843 | 999 | 1,511 | [
"DDInter1793",
"DDInter1149"
] | Thiethylperazine | Mepenzolate | A dopamine antagonist that is particularly useful in treating the nausea and vomiting associated with anesthesia, mildly emetic cancer chemotherapy agents, radiation therapy, and toxins. This piperazine phenothiazine does not prevent vertigo or motion sickness. (From AMA Drug Evaluations Annual, 1994, p457) | Mepenzolate is a post-ganglionic parasympathetic inhibitor. It decreases gastric acid and pepsin secretion and suppresses spontaneous contractions of the colon. Mepenzolate diminishes gastric acid and pepsin secretion. Mepenzolate also suppresses spontaneous contractions of the colon. Pharmacologically, it is a post-ga... | Moderate | 1 | [
[
[
999,
24,
1511
]
],
[
[
999,
25,
675
],
[
675,
24,
1511
]
],
[
[
999,
24,
1192
],
[
1192,
24,
1511
]
],
[
[
999,
63,
352
],
[
352,
... | [
[
[
"Thiethylperazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mepenzolate"
]
],
[
[
"Thiethylperazine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Dextropropoxyphene"
],
... | Thiethylperazine may lead to a major life threatening interaction when taken with Dextropropoxyphene and Dextropropoxyphene may cause a moderate interaction that could exacerbate diseases when taken with Mepenzolate
Thiethylperazine may cause a moderate interaction that could exacerbate diseases when taken with Glycopy... |
DB01276 | DB04575 | 123 | 35 | [
"DDInter706",
"DDInter1555"
] | Exenatide | Quinestrol | Exenatide is a glucagon-like peptide-1 (GLP-1) analog. It activates the GLP-1 receptor and increases insulin secretion, decreases glucagon secretion, and slows gastric emptying to improve glycemic control. Exenatide was given FDA approval on April 28, 2005. It is available as immediate- and extended-release formulation... | The 3-cyclopentyl ether of ethinyl estradiol. | Moderate | 1 | [
[
[
123,
24,
35
]
],
[
[
123,
63,
566
],
[
566,
1,
35
]
],
[
[
123,
24,
984
],
[
984,
40,
35
]
],
[
[
123,
63,
1336
],
[
1336,
40,
... | [
[
[
"Exenatide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Quinestrol"
]
],
[
[
"Exenatide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Levonorgestrel"
],
[
... | Exenatide may cause a moderate interaction that could exacerbate diseases when taken with Levonorgestrel and Levonorgestrel (Compound) resembles Quinestrol (Compound)
Exenatide may cause a moderate interaction that could exacerbate diseases when taken with Danazol and Danazol (Compound) resembles Quinestrol (Compound)
... |
DB01576 | DB06704 | 93 | 247 | [
"DDInter526",
"DDInter951"
] | Dextroamphetamine | Iobenguane (I-123) | Dextroamphetamine is the dextrorotatory enantiomer of amphetamine. Dextroamphetamine was approved by the FDA in 2001 for the treatment of attention deficit hyperactivity disorder[L6010,Label]. | 2-[(3-iodophenyl)methyl]guanidine is an organoiodine compound. | Moderate | 1 | [
[
[
93,
37,
247
]
],
[
[
93,
6,
7390
],
[
7390,
45,
247
]
],
[
[
93,
21,
28787
],
[
28787,
60,
247
]
],
[
[
93,
63,
820
],
[
820,
24... | [
[
[
"Dextroamphetamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v} and {u} may lead to a major life threatening interaction when taken with {v}",
"Iobenguane"
]
],
[
[
"Dextroamphetamine",
"{u} (Compound) binds {v} (Gene)",... | Dextroamphetamine may cause a moderate interaction that could exacerbate diseases when taken with Iobenguane and Dextroamphetamine may lead to a major life threatening interaction when taken with Iobenguane
Dextroamphetamine (Compound) binds SLC6A2 (Gene) and SLC6A2 (Gene) is bound by Iobenguane (Compound)
Dextroamphet... |
DB00023 | DB00208 | 305 | 1,018 | [
"DDInter127",
"DDInter1804"
] | Asparaginase Escherichia coli | Ticlopidine | Asparaginase derived from _Escherichia coli_ (L-asparagine amidohydrolase, EC 3.5.1.1) is an enzyme responsible for the metabolism of L-asparagine, by catalyzing L-asparagine into L-aspartic acid and ammonia. It also facilitates the production of oxaloacetate which is needed for general cellular metabolism. Asparaginas... | Ticlopidine is an effective inhibitor of platelet aggregation. It is a prodrug that is metabolised to an active form, which blocks the ADP receptor that is involved in GPIIb/IIIa receptor activation leading to platelet aggregation. Ticlopidine is marketed under the brand name Ticlid and is indicated for patients who ca... | Moderate | 1 | [
[
[
305,
24,
1018
]
],
[
[
305,
24,
1347
],
[
1347,
64,
1018
]
],
[
[
305,
24,
1486
],
[
1486,
62,
1018
]
],
[
[
305,
24,
1027
],
[
1027,
... | [
[
[
"Asparaginase Escherichia coli",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ticlopidine"
]
],
[
[
"Asparaginase Escherichia coli",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {... | Asparaginase Escherichia coli may cause a moderate interaction that could exacerbate diseases when taken with Clopidogrel and Clopidogrel may lead to a major life threatening interaction when taken with Ticlopidine
Asparaginase Escherichia coli may cause a moderate interaction that could exacerbate diseases when taken ... |
DB00106 | DB05316 | 618 | 749 | [
"DDInter4",
"DDInter1467"
] | Abarelix | Pimavanserin | Synthetic decapeptide antagonist to gonadotropin releasing hormone (GnRH). It is marketed by Praecis Pharmaceuticals as Plenaxis. Praecis announced in June 2006 that it was voluntarily withdrawing the drug from the market. | Pimavanserin is an atypical antipsychotic indicated for the treatment of psychiatric disorders. Although the exact mechanism of action is unknown, it is thought that pimavanserin interacts with the serotonin receptors, particularly the 5-HT<sub>2A</sub> and HT<sub>2C</sub> receptors. Unlike other atypical antipsychotic... | Moderate | 1 | [
[
[
618,
24,
749
]
],
[
[
618,
23,
112
],
[
112,
23,
749
]
],
[
[
618,
24,
1264
],
[
1264,
24,
749
]
],
[
[
618,
24,
594
],
[
594,
6... | [
[
[
"Abarelix",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pimavanserin"
]
],
[
[
"Abarelix",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[
... | Abarelix may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Pimavanserin
Abarelix may cause a moderate interaction that could exacerbate diseases when taken with Doxepin and Doxepin m... |
DB09237 | DB11718 | 1,586 | 927 | [
"DDInter1045",
"DDInter640"
] | Levamlodipine | Encorafenib | Levamlodipine, also known as S-amlodipine, is a pharmacologically active enantiomer of [amlodipine], an antihypertensive medication. Levamlodipine belongs to the dihydropyridine group of calcium channel blockers. This medication was first marketed in Russia and India before being granted FDA approval. The names S-amlod... | Encorafenib, also known as _BRAFTOVI_, is a kinase inhibitor. Encorafenib inhibits BRAF gene, which encodes for B-raf protein, which is a proto-oncogene involved in various genetic mutations. This protein plays a role in regulating the MAP kinase/ERK signaling pathway, which impacts cell division, differentiation, and ... | Moderate | 1 | [
[
[
1586,
24,
927
]
],
[
[
1586,
63,
1324
],
[
1324,
24,
927
]
],
[
[
1586,
24,
484
],
[
484,
63,
927
]
],
[
[
1586,
62,
578
],
[
578,
... | [
[
[
"Levamlodipine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Encorafenib"
]
],
[
[
"Levamlodipine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Troglitazone"
],... | Levamlodipine may cause a moderate interaction that could exacerbate diseases when taken with Troglitazone and Troglitazone may cause a moderate interaction that could exacerbate diseases when taken with Encorafenib
Levamlodipine may cause a moderate interaction that could exacerbate diseases when taken with Entrectini... |
DB00881 | DB09564 | 954 | 1,296 | [
"DDInter1554",
"DDInter930"
] | Quinapril | Insulin degludec | Quinapril is the ethyl ester prodrug of the non-sulfhydryl angiotensin converting enzyme inhibitor quinaprilat.[L8420,L8423] It is used to treat hypertension and heart failure.[L8420,L8423] ACE inhibitors are commonly used as a first line therapy in the treatment of hypertension, along with thiazide diuretics or beta b... | Insulin degludec is an ultra-long-acting form of insulin used for the treatment of hyperglycemia caused by Type 1 and Type 2 Diabetes.[A18561,A18562,A18563,A18564,A174934] Insulin is typically prescribed for the management of diabetes mellitus to mimic the activity of endogenously produced human insulin, a peptide horm... | Moderate | 1 | [
[
[
954,
24,
1296
]
],
[
[
954,
64,
1621
],
[
1621,
23,
1296
]
],
[
[
954,
25,
948
],
[
948,
62,
1296
]
],
[
[
954,
24,
1411
],
[
1411,
... | [
[
[
"Quinapril",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Insulin degludec"
]
],
[
[
"Quinapril",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Potassium chloride"
],
[
... | Quinapril may lead to a major life threatening interaction when taken with Potassium chloride and Potassium chloride may cause a minor interaction that can limit clinical effects when taken with Insulin degludec
Quinapril may lead to a major life threatening interaction when taken with Potassium gluconate and Potassium... |
DB00877 | DB09036 | 629 | 812 | [
"DDInter1678",
"DDInter1668"
] | Sirolimus | Siltuximab | Sirolimus, also known as rapamycin, is a macrocyclic lactone antibiotic produced by bacteria _Streptomyces hygroscopicus_, which was isolated from the soil of the Vai Atari region of Rapa Nui (Easter Island). It was first isolated and identified as an antifungal agent with potent anticandida activity; however, after it... | Siltuximab is a chimeric (human-mouse) monoclonal immunoglobulin G1-kappa antibody produced in a Chinese hamster ovary (CHO) cell line by recombinant DNA technology. Siltuximab prevents the binding of IL-6 to soluble and membrane-bound IL-6 receptors by forming high affinity complexes with human interleukin-6 (IL-6). I... | Moderate | 1 | [
[
[
629,
24,
812
]
],
[
[
629,
23,
1193
],
[
1193,
62,
812
]
],
[
[
629,
62,
1461
],
[
1461,
23,
812
]
],
[
[
629,
24,
287
],
[
287,
... | [
[
[
"Sirolimus",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Siltuximab"
]
],
[
[
"Sirolimus",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Zinc gluconate"
],
[
... | Sirolimus may cause a minor interaction that can limit clinical effects when taken with Zinc gluconate and Zinc gluconate may cause a minor interaction that can limit clinical effects when taken with Siltuximab
Sirolimus may cause a minor interaction that can limit clinical effects when taken with Vitamin E and Vitamin... |
DB06674 | DB16582 | 908 | 899 | [
"DDInter837",
"DDInter1080"
] | Golimumab | Lisocabtagene maraleucel | Golimumab is a human IgG1қ monoclonal antibody derived from immunizing genetically engineered mice with human TNFα. Golimumab binds and inhibits soluble and transmembrane human TNFα. Increased TNFα is associated with chronic inflammation. Thus golimumab is indicated for use in adults (i) as an adjunct to methotrexate t... | Lisocabtagene maraleucel is a chimeric antigen receptor (CAR) T-cell therapy, similar to [brexucabtagene autoleucel] and [axicabtagene ciloleucel].[A228493,L31588] Lisocabtagene maraleucel is a genetically modified autologous T-cell therapy that targets CD19, the B-lymphocyte surface antigen B4. CAR T-cell therapy has ... | Major | 2 | [
[
[
908,
25,
899
]
],
[
[
908,
64,
869
],
[
869,
24,
899
]
],
[
[
908,
25,
1362
],
[
1362,
24,
899
]
],
[
[
908,
24,
1430
],
[
1430,
... | [
[
[
"Golimumab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Lisocabtagene maraleucel"
]
],
[
[
"Golimumab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Topotecan"
],
[
"Topotecan",
... | Golimumab may lead to a major life threatening interaction when taken with Topotecan and Topotecan may cause a moderate interaction that could exacerbate diseases when taken with Lisocabtagene maraleucel
Golimumab may lead to a major life threatening interaction when taken with Olaparib and Olaparib may cause a moderat... |
DB00365 | DB09038 | 839 | 1,450 | [
"DDInter842",
"DDInter636"
] | Grepafloxacin | Empagliflozin | Grepafloxacin is an oral broad-spectrum quinoline antibacterial agent used to treat bacterial infections. Due to the QTc-prolonging potential, as indicated by the changes in the QT interval on the electrocardiogram, and the risk for cardiovascular adverse events, grepafloxacin was withdrawn in the United States. | Empagliflozin is an inhibitor of sodium-glucose co-transporter-2 (SGLT2), the transporters primarily responsible for the reabsorption of glucose in the kidney. It is used clinically as an adjunct to diet and exercise, often in combination with other drug therapies,[L13673,L13679,L11479] for the management of type 2 dia... | Moderate | 1 | [
[
[
839,
24,
1450
]
],
[
[
839,
25,
485
],
[
485,
24,
1450
]
],
[
[
839,
24,
659
],
[
659,
63,
1450
]
],
[
[
839,
64,
1179
],
[
1179,
... | [
[
[
"Grepafloxacin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Empagliflozin"
]
],
[
[
"Grepafloxacin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Pentamidine"
],
[
"... | Grepafloxacin may lead to a major life threatening interaction when taken with Pentamidine and Pentamidine may cause a moderate interaction that could exacerbate diseases when taken with Empagliflozin
Grepafloxacin may cause a moderate interaction that could exacerbate diseases when taken with Vilanterol and Vilanterol... |
DB00372 | DB13928 | 999 | 1,385 | [
"DDInter1793",
"DDInter1660"
] | Thiethylperazine | Semaglutide | A dopamine antagonist that is particularly useful in treating the nausea and vomiting associated with anesthesia, mildly emetic cancer chemotherapy agents, radiation therapy, and toxins. This piperazine phenothiazine does not prevent vertigo or motion sickness. (From AMA Drug Evaluations Annual, 1994, p457) | Semaglutide is a glucagon-like peptide 1 (GLP-1) analog used to manage type 2 diabetes along with lifestyle changes, such as dietary restrictions and increased physical activity.[A31421,L8681] Other members of this drug class include [Exenatide] and [Liraglutide]. Semaglutide was developed by Novo Nordisk and approved ... | Moderate | 1 | [
[
[
999,
24,
1385
]
],
[
[
999,
24,
1399
],
[
1399,
63,
1385
]
],
[
[
999,
24,
359
],
[
359,
24,
1385
]
],
[
[
999,
63,
1028
],
[
1028,
... | [
[
[
"Thiethylperazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Semaglutide"
]
],
[
[
"Thiethylperazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lithium carbon... | Thiethylperazine may cause a moderate interaction that could exacerbate diseases when taken with Lithium carbonate and Lithium carbonate may cause a moderate interaction that could exacerbate diseases when taken with Semaglutide
Thiethylperazine may cause a moderate interaction that could exacerbate diseases when taken... |
DB00862 | DB09112 | 1,005 | 1,455 | [
"DDInter1918",
"DDInter1306"
] | Vardenafil | Nitrous acid | Vardenafil is a selective inhibitor of cyclic guanosine monophosphate (cGMP)-specific phosphodiesterase type 5 (PDE5) and an oral therapy for the treatment of erectile dysfunction.[L45563,L45568] During sexual stimulation, nitric oxide (NO) is released from nerve endings and endothelial cells in the corpus cavernosum, ... | Nitrous acid (as sodium nitrite) is used as part of an intravenous mixture with sodium thiosulfate to treat cyanide poisoning. It is on the World Health Organization's List of Essential Medicines, a list of the most important medications needed in a basic health system. There is also research to investigate its applica... | Moderate | 1 | [
[
[
1005,
24,
1455
]
],
[
[
1005,
24,
1450
],
[
1450,
24,
1455
]
],
[
[
1005,
63,
1214
],
[
1214,
24,
1455
]
],
[
[
1005,
24,
433
],
[
433... | [
[
[
"Vardenafil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nitrous acid"
]
],
[
[
"Vardenafil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Empagliflozin"
],
... | Vardenafil may cause a moderate interaction that could exacerbate diseases when taken with Empagliflozin and Empagliflozin may cause a moderate interaction that could exacerbate diseases when taken with Nitrous acid
Vardenafil may cause a moderate interaction that could exacerbate diseases when taken with Minoxidil and... |
DB00023 | DB00398 | 305 | 79 | [
"DDInter127",
"DDInter1702"
] | Asparaginase Escherichia coli | Sorafenib | Asparaginase derived from _Escherichia coli_ (L-asparagine amidohydrolase, EC 3.5.1.1) is an enzyme responsible for the metabolism of L-asparagine, by catalyzing L-asparagine into L-aspartic acid and ammonia. It also facilitates the production of oxaloacetate which is needed for general cellular metabolism. Asparaginas... | Sorafenib is a bi-aryl urea and an oral multikinase inhibitor. It targets cell surface tyrosine kinase receptors and downstream intracellular kinases that are implicated in tumour cell proliferation and tumour angiogenesis. First approved by the FDA and European Commission in 2007 for the treatment of hepatocellular ca... | Moderate | 1 | [
[
[
305,
24,
79
]
],
[
[
305,
24,
292
],
[
292,
40,
79
]
],
[
[
305,
24,
549
],
[
549,
62,
79
]
],
[
[
305,
24,
126
],
[
126,
63,
... | [
[
[
"Asparaginase Escherichia coli",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sorafenib"
]
],
[
[
"Asparaginase Escherichia coli",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}... | Asparaginase Escherichia coli may cause a moderate interaction that could exacerbate diseases when taken with Regorafenib and Regorafenib (Compound) resembles Sorafenib (Compound)
Asparaginase Escherichia coli may cause a moderate interaction that could exacerbate diseases when taken with Dapagliflozin and Dapagliflozi... |
DB00401 | DB11126 | 84 | 900 | [
"DDInter1298",
"DDInter276"
] | Nisoldipine | Calcium gluconate | Nisoldipine is a 1,4-dihydropyridine calcium channel blocker. It acts primarily on vascular smooth muscle cells by stabilizing voltage-gated L-type calcium channels in their inactive conformation. By inhibiting the influx of calcium in smooth muscle cells, nisoldipine prevents calcium-dependent smooth muscle contractio... | Calcium gluconate is used as mineral supplement and medication when there is insufficient calcium in the diet. Supplementation may be done to treat or prevent osteoporosis or rickets, consequences of hypocalcemia. It can also be taken by mouth but is not recommended by injection into a muscle. Calcium Gluconate Injecti... | Moderate | 1 | [
[
[
84,
24,
900
]
],
[
[
84,
1,
336
],
[
336,
24,
900
]
],
[
[
84,
40,
1428
],
[
1428,
24,
900
]
],
[
[
84,
1,
336
],
[
336,
40,
... | [
[
[
"Nisoldipine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Calcium gluconate"
]
],
[
[
"Nisoldipine",
"{u} (Compound) resembles {v} (Compound)",
"Nifedipine"
],
[
"Nifedipine",
"{u} may cause ... | Nisoldipine (Compound) resembles Nifedipine (Compound) and Nifedipine may cause a moderate interaction that could exacerbate diseases when taken with Calcium gluconate
Nisoldipine (Compound) resembles Isradipine (Compound) and Isradipine may cause a moderate interaction that could exacerbate diseases when taken with Ca... |
DB00562 | DB08907 | 1,014 | 1,344 | [
"DDInter188",
"DDInter280"
] | Benzthiazide | Canagliflozin | Benzthiazide is used to treat hypertension and edema. Like other thiazides, benzthiazide promotes water loss from the body (diuretics). They inhibit Na+/Cl- reabsorption from the distal convoluted tubules in the kidneys. Thiazides also cause loss of potassium and an increase in serum uric acid. Thiazides are often used... | Canagliflozin, also known as _Invokana_, is a sodium-glucose cotransporter 2 (SGLT2) inhibitor used in the management of type 2 diabetes mellitus along with lifestyle changes including diet and exercise [FDA label]. It was initially approved by the FDA in 2013 for the management of diabetes and later approved in 2018 f... | Moderate | 1 | [
[
[
1014,
24,
1344
]
],
[
[
1014,
24,
549
],
[
549,
1,
1344
]
],
[
[
1014,
24,
1486
],
[
1486,
24,
1344
]
],
[
[
1014,
63,
176
],
[
176,
... | [
[
[
"Benzthiazide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Canagliflozin"
]
],
[
[
"Benzthiazide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dapagliflozin"
]... | Benzthiazide may cause a moderate interaction that could exacerbate diseases when taken with Dapagliflozin and Dapagliflozin (Compound) resembles Canagliflozin (Compound)
Benzthiazide may cause a moderate interaction that could exacerbate diseases when taken with Methylprednisolone and Methylprednisolone may cause a mo... |
DB05528 | DB06273 | 1,070 | 980 | [
"DDInter1228",
"DDInter1824"
] | Mipomersen | Tocilizumab | Mipomersen sodium, which was known as the investigational drug, isis-301012, is the salt form of a synthetic phosphorothioate oligonucleotide. Mipomersen sodium prevents the formation of apo B-100, resulting in a decrease in the levels of apolipoprotein B (apo B), low density lipoprotein (LDL), and total cholesterol. M... | Tocilizumab is a recombinant humanized monoclonal antibody IL-6 receptor inhibitor used to treat inflammatory and autoimmune conditions. It was first described in the literature in 2003 when Chugai, a subsidiary of Roche began developing IL-6 inhibiting monoclonal antibodies. Tocilizumab was granted FDA approval on 8 J... | Major | 2 | [
[
[
1070,
25,
980
]
],
[
[
1070,
25,
850
],
[
850,
63,
980
]
],
[
[
1070,
64,
467
],
[
467,
24,
980
]
],
[
[
1070,
25,
1047
],
[
1047,
... | [
[
[
"Mipomersen",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Tocilizumab"
]
],
[
[
"Mipomersen",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Brentuximab vedotin"
],
[
"Brentuximab ved... | Mipomersen may lead to a major life threatening interaction when taken with Brentuximab vedotin and Brentuximab vedotin may cause a moderate interaction that could exacerbate diseases when taken with Tocilizumab
Mipomersen may lead to a major life threatening interaction when taken with Simvastatin and Simvastatin may ... |
DB08826 | DB14375 | 1,292 | 644 | [
"DDInter489",
"DDInter1219"
] | Deferiprone | Milk thistle | Deferiprone is an oral iron chelator used as a second line agent in thalassemia syndromes when iron overload from blood transfusions occurs. Thalassemias are a type of hereditary anaemia due a defect in the production of hemoglobin. As a result, erythropoiesis, the production of new red blood cells, is impaired. FDA ap... | Milk thistle is a plant/plant extract used in some OTC (over-the-counter) products. It is not an approved drug. | Moderate | 1 | [
[
[
1292,
24,
644
]
]
] | [
[
[
"Deferiprone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Milk thistle"
]
]
] | |
DB00687 | DB01001 | 870 | 688 | [
"DDInter747",
"DDInter1632"
] | Fludrocortisone | Salbutamol | Fludrocortisone is a synthetic mineralocorticoid used in conjunction with [hydrocortisone] to replace missing endogenous corticosteroids in patients with adrenal insufficiency.[A187169,A187187] It is functionally similar to [aldosterone], the body's primary endogenous mineralocorticoid, and is structurally analogous to... | Salbutamol is a short-acting, selective beta2-adrenergic receptor agonist used in the treatment of asthma and COPD. It is 29 times more selective for beta2 receptors than beta1 receptors giving it higher specificity for pulmonary beta receptors versus beta1-adrenergic receptors located in the heart. Salbutamol is formu... | Minor | 0 | [
[
[
870,
23,
688
]
],
[
[
870,
23,
455
],
[
455,
24,
688
]
],
[
[
870,
23,
1148
],
[
1148,
63,
688
]
],
[
[
870,
21,
28714
],
[
28714,
... | [
[
[
"Fludrocortisone",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Salbutamol"
]
],
[
[
"Fludrocortisone",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Salmeterol"
],
... | Fludrocortisone may cause a minor interaction that can limit clinical effects when taken with Salmeterol and Salmeterol may cause a moderate interaction that could exacerbate diseases when taken with Salbutamol
Fludrocortisone may cause a minor interaction that can limit clinical effects when taken with Isoprenaline an... |
DB00980 | DB11130 | 969 | 407 | [
"DDInter1564",
"DDInter1344"
] | Ramelteon | Opium | Ramelteon is the first in a new class of sleep agents that selectively binds to the melatonin receptors in the suprachiasmatic nucleus (SCN). It is used for insomnia, particularly delayed sleep onset. Ramelteon has not been shown to produce dependence and has shown no potential for abuse. | Opium is the first substance of the diverse group of the opiates. It has been known for a long time, and the first evidence of a poppy culture dates from 5 thousand years by the Sumerians. During the years, opium was used as a sedative and hypnotic, but it was determined to be addictive. Opium is extracted from _Papave... | Moderate | 1 | [
[
[
969,
24,
407
]
],
[
[
969,
63,
662
],
[
662,
24,
407
]
],
[
[
969,
24,
849
],
[
849,
24,
407
]
],
[
[
969,
64,
475
],
[
475,
24,... | [
[
[
"Ramelteon",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Opium"
]
],
[
[
"Ramelteon",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Carbinoxamine"
],
[
... | Ramelteon may cause a moderate interaction that could exacerbate diseases when taken with Carbinoxamine and Carbinoxamine may cause a moderate interaction that could exacerbate diseases when taken with Opium
Ramelteon may cause a moderate interaction that could exacerbate diseases when taken with Mepyramine and Mepyram... |
DB00047 | DB00059 | 176 | 1,560 | [
"DDInter932",
"DDInter1404"
] | Insulin glargine | Pegaspargase | Insulin glargine is a long-acting form of insulin used for the treatment of hyperglycemia caused by Type 1 and Type 2 Diabetes. Insulin is typically prescribed for the management of diabetes mellitus to mimic the activity of endogenously produced human insulin, a peptide hormone produced by beta cells of the pancreas t... | Pegaspargase is a conjugate of monomethoxypolyethylene glycol (mPEG) and L-asparaginase (L-asparagine amidohydrolase), an asparagine-specific enzyme that converts L-asparagine into aspartic acid and ammonia. Asparagine is an amino acid that is vital for cell survival. In humans, most normal tissues can produce asparagi... | Moderate | 1 | [
[
[
176,
24,
1560
]
],
[
[
176,
24,
1021
],
[
1021,
63,
1560
]
],
[
[
176,
25,
1299
],
[
1299,
63,
1560
]
],
[
[
176,
24,
695
],
[
695,
... | [
[
[
"Insulin glargine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pegaspargase"
]
],
[
[
"Insulin glargine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pramlintide"
... | Insulin glargine may cause a moderate interaction that could exacerbate diseases when taken with Pramlintide and Pramlintide may cause a moderate interaction that could exacerbate diseases when taken with Pegaspargase
Insulin glargine may lead to a major life threatening interaction when taken with Trovafloxacin and Tr... |
DB00372 | DB01041 | 999 | 770 | [
"DDInter1793",
"DDInter1789"
] | Thiethylperazine | Thalidomide | A dopamine antagonist that is particularly useful in treating the nausea and vomiting associated with anesthesia, mildly emetic cancer chemotherapy agents, radiation therapy, and toxins. This piperazine phenothiazine does not prevent vertigo or motion sickness. (From AMA Drug Evaluations Annual, 1994, p457) | A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, thalidomide was withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of inflammatory disorders and cancers. Thalidomide displays immunosuppressive and anti-angiogenic activity through modulating ... | Moderate | 1 | [
[
[
999,
24,
770
]
],
[
[
999,
24,
849
],
[
849,
63,
770
]
],
[
[
999,
24,
1533
],
[
1533,
24,
770
]
],
[
[
999,
25,
684
],
[
684,
2... | [
[
[
"Thiethylperazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Thalidomide"
]
],
[
[
"Thiethylperazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mepyramine"
... | Thiethylperazine may cause a moderate interaction that could exacerbate diseases when taken with Mepyramine and Mepyramine may cause a moderate interaction that could exacerbate diseases when taken with Thalidomide
Thiethylperazine may cause a moderate interaction that could exacerbate diseases when taken with Entacapo... |
DB00635 | DB09473 | 1,573 | 884 | [
"DDInter1515",
"DDInter918"
] | Prednisone | Indium In-111 oxyquinoline | A synthetic anti-inflammatory glucocorticoid derived from [cortisone]. It is biologically inert and converted to [prednisolone] in the liver. Prednisone was granted FDA approval on 21 February 1955. | Indium In 111 oxyquinoline (oxine) is a diagnostic radiopharmaceutical intended for radiolabeling of autologous leukocytes. It is composed of a 3:1 saturated complex of In-111 isotope and oxyquinoline. Indium-111 decays by isomeric transition and electron capture to cadmium-111, emitting a gamma ray that can be detecte... | Moderate | 1 | [
[
[
1573,
24,
884
]
],
[
[
1573,
1,
423
],
[
423,
24,
884
]
],
[
[
1573,
40,
870
],
[
870,
24,
884
]
],
[
[
1573,
24,
609
],
[
609,
... | [
[
[
"Prednisone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Indium In-111 oxyquinoline"
]
],
[
[
"Prednisone",
"{u} (Compound) resembles {v} (Compound)",
"Ciclesonide"
],
[
"Ciclesonide",
"{u} m... | Prednisone (Compound) resembles Ciclesonide (Compound) and Ciclesonide may cause a moderate interaction that could exacerbate diseases when taken with Indium In-111 oxyquinoline
Prednisone (Compound) resembles Fludrocortisone (Compound) and Fludrocortisone may cause a moderate interaction that could exacerbate diseases... |
DB01254 | DB14509 | 1,213 | 1,399 | [
"DDInter484",
"DDInter1081"
] | Dasatinib | Lithium carbonate | Dasatinib is an orally available multikinase inhibitor indicated for the treatment of Philadelphia chromosome (Ph)-positive leukemias.[A2224,L45171] Ph is a chromosomal abnormality found in patients with chronic myelogenous leukemia (CML) and acute lymphocytic leukemia (ALL), where the ABL tyrosine kinase and the break... | Lithium has been used to treat manic episodes since the 19th century. Though it is widely used, its mechanism of action is still unknown[FDA Label][A14585,A176642,A176651,L5843]. Lithium carbonate has a narrow therapeutic range and so careful monitoring is required to avoid adverse effects[FDA Label]. | Moderate | 1 | [
[
[
1213,
24,
1399
]
],
[
[
1213,
64,
1479
],
[
1479,
23,
1399
]
],
[
[
1213,
24,
1374
],
[
1374,
24,
1399
]
],
[
[
1213,
63,
820
],
[
820... | [
[
[
"Dasatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lithium carbonate"
]
],
[
[
"Dasatinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Acetylsalicylic acid"
],
[
... | Dasatinib may lead to a major life threatening interaction when taken with Acetylsalicylic acid and Acetylsalicylic acid may cause a minor interaction that can limit clinical effects when taken with Lithium carbonate
Dasatinib may cause a moderate interaction that could exacerbate diseases when taken with Abiraterone a... |
DB00470 | DB14881 | 530 | 180 | [
"DDInter601",
"DDInter1329"
] | Dronabinol | Oliceridine | Dronabinol (marketed as Marinol) is a synthetic form of delta-9-tetrahydrocannabinol (Δ⁹-THC), the primary psychoactive component of cannabis (marijuana). THC demonstrates its effects through weak partial agonist activity at Cannabinoid-1 (CB1R) and Cannabinoid-2 (CB2R) receptors, which results in the well-known effect... | Severe acute pain occurs through nociceptive signalling involving both ascending and descending spinal pathways, in which nerve conductance is mediated in part by the action of opioid receptors.[A218041, A218046] Opioid receptors are seven-transmembrane G-protein-coupled receptors (GPCRs), of which the μ-opioid recepto... | Moderate | 1 | [
[
[
530,
24,
180
]
],
[
[
530,
24,
401
],
[
401,
24,
180
]
],
[
[
530,
63,
1648
],
[
1648,
24,
180
]
],
[
[
530,
1,
1614
],
[
1614,
... | [
[
[
"Dronabinol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Oliceridine"
]
],
[
[
"Dronabinol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Promethazine"
],
[... | Dronabinol may cause a moderate interaction that could exacerbate diseases when taken with Promethazine and Promethazine may cause a moderate interaction that could exacerbate diseases when taken with Oliceridine
Dronabinol may cause a moderate interaction that could exacerbate diseases when taken with Aldesleukin and ... |
DB08870 | DB14731 | 850 | 1,518 | [
"DDInter228",
"DDInter1741"
] | Brentuximab vedotin | Tagraxofusp | Brentuximab vedotin, also known as Adcetris®, is an antibody-drug conjugate that combines an anti-CD30 antibody with the drug monomethyl auristatin E (MMAE). It is an anti-neoplastic agent used in the treatment of Hodgkin's lymphoma and systemic anaplastic large-cell lymphoma. Brentuximab vedotin was initially approved... | Tagraxofusp is a CD123-directed cytotoxin. It is a fusion protein composed of a human interleukin-3 (IL-3) that is genetically fused to the catalytic and translocation domains of truncated diphtheria toxin (DT) produced in _Escherichia coli_.[A253762, A253887, L43702] Tagraxofusp received its first global approval by t... | Moderate | 1 | [
[
[
850,
24,
1518
]
],
[
[
850,
63,
123
],
[
123,
24,
1518
]
],
[
[
850,
24,
135
],
[
135,
24,
1518
]
],
[
[
850,
24,
242
],
[
242,
... | [
[
[
"Brentuximab vedotin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tagraxofusp"
]
],
[
[
"Brentuximab vedotin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Exenatid... | Brentuximab vedotin may cause a moderate interaction that could exacerbate diseases when taken with Exenatide and Exenatide may cause a moderate interaction that could exacerbate diseases when taken with Tagraxofusp
Brentuximab vedotin may cause a moderate interaction that could exacerbate diseases when taken with Albi... |
DB00191 | DB11827 | 73 | 433 | [
"DDInter1447",
"DDInter669"
] | Phentermine | Ertugliflozin | Phentermine is a sympathomimetic amine anorectic agent and it was introduced in 1959 as part of an anti-obesity combination drug.[A174361, A174364] It is chemically related to amphetamine and it is commonly referred to as an atypical amphetamine. Phentermine has not been reported an addictive potential which allows thi... | Ertugliflozin is a sodium-dependent glucose cotransporter-2 (SGLT2) inhibitor used to treat type II diabetes mellitus. It works to block glucose reabsorption from the glomerulus. Ertugliflozin was first approved by the FDA in December 2017.[A261951, L1132] It was also approved by the European Commission in March 2018. | Moderate | 1 | [
[
[
73,
24,
433
]
],
[
[
73,
24,
959
],
[
959,
24,
433
]
],
[
[
73,
25,
1466
],
[
1466,
24,
433
]
],
[
[
73,
35,
280
],
[
280,
24,
... | [
[
[
"Phentermine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ertugliflozin"
]
],
[
[
"Phentermine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Glipizide"
],
... | Phentermine may cause a moderate interaction that could exacerbate diseases when taken with Glipizide and Glipizide may cause a moderate interaction that could exacerbate diseases when taken with Ertugliflozin
Phentermine may lead to a major life threatening interaction when taken with Phenylpropanolamine and Phenylpro... |
DB00624 | DB12332 | 1,561 | 1,619 | [
"DDInter1775",
"DDInter1626"
] | Testosterone | Rucaparib | Testosterone is a steroid sex hormone indicated to treat primary hypogonadism and hypogonadotropic hypogonadism.[L8983,L8935,L8938,L8986,L8989,L8992,L8995] Testosterone antagonizes the androgen receptor to induce gene expression that causes the growth and development of masculine sex organs and secondary sexual charact... | Rucaparib is an anticancer drug and poly (ADP-ribose) polymerase (PARP) inhibitor. PARP is an enzyme that plays an essential role in DNA repair. Rucaparib is proposed to work in several PARP-dependent and PARP-independent mechanisms of action; however, it causes a unique effect of synthetic lethality. By targeting the ... | Moderate | 1 | [
[
[
1561,
24,
1619
]
],
[
[
1561,
63,
1419
],
[
1419,
24,
1619
]
],
[
[
1561,
24,
1213
],
[
1213,
24,
1619
]
],
[
[
1561,
40,
1438
],
[
14... | [
[
[
"Testosterone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rucaparib"
]
],
[
[
"Testosterone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Imatinib"
],
[
... | Testosterone may cause a moderate interaction that could exacerbate diseases when taken with Imatinib and Imatinib may cause a moderate interaction that could exacerbate diseases when taken with Rucaparib
Testosterone may cause a moderate interaction that could exacerbate diseases when taken with Dasatinib and Dasatini... |
DB01261 | DB11901 | 170 | 913 | [
"DDInter1679",
"DDInter107"
] | Sitagliptin | Apalutamide | Sitagliptin is an oral dipeptidyl peptidase-4 (DPP-4) inhibitor used in conjunction with diet and exercise to improve glycemic control in patients with type 2 diabetes mellitus[FDA label,A2260,A2255,A2256]. The effect of this medication leads to glucose dependent increases in insulin and decreases in glucagon to improv... | Apalutamide is a potent androgen receptor (AR) antagonist that selectively binds to the ligand-binding domain of AR and blocks AR nuclear translocation or binding to androgen response elements . It has been used in trials studying the treatment of Prostate Cancer, Hepatic Impairment, Prostatic Neoplasms, Castration-Res... | Moderate | 1 | [
[
[
170,
24,
913
]
],
[
[
170,
24,
1060
],
[
1060,
62,
913
]
],
[
[
170,
63,
303
],
[
303,
24,
913
]
],
[
[
170,
24,
35
],
[
35,
24,... | [
[
[
"Sitagliptin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Apalutamide"
]
],
[
[
"Sitagliptin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Enfortumab vedotin"
... | Sitagliptin may cause a moderate interaction that could exacerbate diseases when taken with Enfortumab vedotin and Enfortumab vedotin may cause a minor interaction that can limit clinical effects when taken with Apalutamide
Sitagliptin may cause a moderate interaction that could exacerbate diseases when taken with Medr... |
DB00675 | DB08881 | 888 | 868 | [
"DDInter1744",
"DDInter1925"
] | Tamoxifen | Vemurafenib | Tamoxifen is a non-steroidal antiestrogen used to treat estrogen receptor positive breast cancers as well as prevent the incidence of breast cancer in high risk populations.[A1025,L7799,L7802] Tamoxifen is used alone or as an adjuvant in these treatments.[L7799,L7802] Tamoxifen may no longer be the preferred treatment ... | Vemurafenib is a competitive kinase inhibitor with activity against BRAF kinase with mutations like V600E. It exerts its function by binding to the ATP-binding domain of the mutant BRAF. Vemurafenib was co-developed by Roche and Plexxikon and it obtained its FDA approval on August 17, 2011, under the company Hoffmann L... | Major | 2 | [
[
[
888,
25,
868
]
],
[
[
888,
6,
8374
],
[
8374,
45,
868
]
],
[
[
888,
18,
6123
],
[
6123,
46,
868
]
],
[
[
888,
7,
7161
],
[
7161,
... | [
[
[
"Tamoxifen",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Vemurafenib"
]
],
[
[
"Tamoxifen",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
"Vemurafe... | Tamoxifen (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Vemurafenib (Compound)
Tamoxifen (Compound) downregulates PYCR1 (Gene) and PYCR1 (Gene) is upregulated by Vemurafenib (Compound)
Tamoxifen (Compound) upregulates KLHDC2 (Gene) and KLHDC2 (Gene) is upregulated by Vemurafenib (Compound)
Tamoxifen (Com... |
DB01105 | DB09054 | 222 | 384 | [
"DDInter1665",
"DDInter905"
] | Sibutramine | Idelalisib | Sibutramine (trade name Meridia in the USA, Reductil in Europe and other countries), usually as sibutramide hydrochloride monohydrate, is an orally administered agent for the treatment of obesity. It is a centrally acting stimulant chemically related to amphetamines thus it is classified as a Schedule IV controlled sub... | Idelalisib is a phosphoinositide 3-kinase inhibitor indicated in the treatment of chronic lymphocytic leukemia (CLL), relapsed follicular B-cell non-Hodgkin lymphoma (FL), and relapsed small lymphocytic lymphoma (SLL). For the treatment of relapsed CLL, it is currently indicated as a second-line agent in combination wi... | Minor | 0 | [
[
[
222,
23,
384
]
],
[
[
222,
25,
318
],
[
318,
23,
384
]
],
[
[
222,
64,
1230
],
[
1230,
23,
384
]
],
[
[
222,
24,
1627
],
[
1627,
... | [
[
[
"Sibutramine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Idelalisib"
]
],
[
[
"Sibutramine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Escitalopram"
],
[
"Escitalo... | Sibutramine may lead to a major life threatening interaction when taken with Escitalopram and Escitalopram may cause a minor interaction that can limit clinical effects when taken with Idelalisib
Sibutramine may lead to a major life threatening interaction when taken with Citalopram and Citalopram may cause a minor int... |
DB00366 | DB01178 | 1,594 | 369 | [
"DDInter600",
"DDInter357"
] | Doxylamine | Chlormezanone | Histamine H1 antagonist with pronounced sedative properties. It is used in allergies and as an antitussive, antiemetic, and hypnotic. Doxylamine has also been administered in veterinary applications and was formerly used in parkinsonism. | A non-benzodiazepine that is used in the management of anxiety. It has been suggested for use in the treatment of muscle spasm. | Moderate | 1 | [
[
[
1594,
24,
369
]
],
[
[
1594,
24,
1532
],
[
1532,
63,
369
]
],
[
[
1594,
35,
272
],
[
272,
24,
369
]
],
[
[
1594,
24,
13
],
[
13,
... | [
[
[
"Doxylamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Chlormezanone"
]
],
[
[
"Doxylamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ifosfamide"
],
[... | Doxylamine may cause a moderate interaction that could exacerbate diseases when taken with Ifosfamide and Ifosfamide may cause a moderate interaction that could exacerbate diseases when taken with Chlormezanone
Doxylamine (Compound) resembles Chlorpheniramine (Compound) and Doxylamine may cause a moderate interaction t... |
DB01045 | DB04868 | 463 | 478 | [
"DDInter1590",
"DDInter1293"
] | Rifampicin | Nilotinib | A semisynthetic antibiotic produced from Streptomyces mediterranei. It has a broad antibacterial spectrum, including activity against several forms of Mycobacterium. In susceptible organisms it inhibits DNA-dependent RNA polymerase activity by forming a stable complex with the enzyme. It thus suppresses the initiation ... | Nilotinib, also known as AMN107, is a tyrosine kinase inhibitor under investigation as a possible treatment for chronic myelogenous leukemia (CML). A Phase I clinical trial in 2006 showed that this drug was relatively safe and offered significant therapeutic benefits in cases of CML which were found to be resistant to ... | Major | 2 | [
[
[
463,
25,
478
]
],
[
[
463,
24,
1468
],
[
1468,
63,
478
]
],
[
[
463,
6,
6017
],
[
6017,
45,
478
]
],
[
[
463,
25,
1135
],
[
1135,
... | [
[
[
"Rifampicin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Nilotinib"
]
],
[
[
"Rifampicin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ponatinib"
],
[
"Ponatinib",
... | Rifampicin may cause a moderate interaction that could exacerbate diseases when taken with Ponatinib and Ponatinib may cause a moderate interaction that could exacerbate diseases when taken with Nilotinib
Rifampicin (Compound) binds CYP2C9 (Gene) and CYP2C9 (Gene) is bound by Nilotinib (Compound)
Rifampicin may lead to... |
DB00480 | DB09035 | 1,668 | 410 | [
"DDInter1035",
"DDInter1308"
] | Lenalidomide | Nivolumab | Lenalidomide (previously referred to as CC-5013) is an immunomodulatory drug with potent antineoplastic, anti-angiogenic, and anti-inflammatory properties. It is a 4-amino-glutamyl analogue of [thalidomide] and like thalidomide, lenalidomide exists as a racemic mixture of the active S(-) and R(+) forms. However, lenali... | Nivolumab is a fully human IgG4 antibody targeting the immune checkpoint programmed death receptor-1 (PD-1). This antibody was produced entirely in mice and grafted onto human kappa and IgG4 Fc region with the mutation _S228P_ for additional stability and reduced variability. It was developed by Bristol Myers Squibb. N... | Major | 2 | [
[
[
1668,
25,
410
]
],
[
[
1668,
24,
384
],
[
384,
63,
410
]
],
[
[
1668,
1,
770
],
[
770,
25,
410
]
],
[
[
1668,
24,
384
],
[
384,
... | [
[
[
"Lenalidomide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Nivolumab"
]
],
[
[
"Lenalidomide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Idelalisib"
],
[
"Idelali... | Lenalidomide may cause a moderate interaction that could exacerbate diseases when taken with Idelalisib and Idelalisib may cause a moderate interaction that could exacerbate diseases when taken with Nivolumab
Lenalidomide (Compound) resembles Thalidomide (Compound) and Thalidomide may lead to a major life threatening i... |
DB08879 | DB11817 | 632 | 1,259 | [
"DDInter173",
"DDInter165"
] | Belimumab | Baricitinib | Belimumab is a fully human recombinant IgG1λ monoclonal antibody that inhibits soluble human B lymphocyte stimulator protein (BLyS, also referred to as BAFF and TNFSF13B), a B cell survival factor. BLyS levels are often elevated in immunodeficient and autoimmune disorders, such as systemic lupus erythematosus (SLE).[A2... | Baricitinib is a Janus kinase (JAK) inhibitor. JAKs are tyrosine protein kinases that play an important role in pro-inflammatory signaling pathways. Overactive JAKs have been implicated in autoimmune disorders, such as rheumatoid arthritis. By inhibiting the actions of JAK1 and JAK2, baricitinib attenuates JAK-mediated... | Major | 2 | [
[
[
632,
25,
1259
]
],
[
[
632,
23,
1193
],
[
1193,
23,
1259
]
],
[
[
632,
62,
1461
],
[
1461,
23,
1259
]
],
[
[
632,
24,
949
],
[
949,
... | [
[
[
"Belimumab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Baricitinib"
]
],
[
[
"Belimumab",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Zinc gluconate"
],
[
"Zinc gluc... | Belimumab may cause a minor interaction that can limit clinical effects when taken with Zinc gluconate and Zinc gluconate may cause a minor interaction that can limit clinical effects when taken with Baricitinib
Belimumab may cause a minor interaction that can limit clinical effects when taken with Vitamin E and Vitami... |
DB00880 | DB00912 | 359 | 473 | [
"DDInter360",
"DDInter1581"
] | Chlorothiazide | Repaglinide | A thiazide diuretic with actions and uses similar to those of hydrochlorothiazide. (From Martindale, The Extra Pharmacopoeia, 30th ed, p812) | Repaglinide is an oral antihyperglycemic agent used for the treatment of non-insulin-dependent diabetes mellitus (NIDDM). It belongs to the meglitinide class of short-acting insulin secretagogues, which act by binding to β cells of the pancreas to stimulate insulin release. Repaglinide induces an early insulin response... | Moderate | 1 | [
[
[
359,
24,
473
]
],
[
[
359,
21,
28873
],
[
28873,
60,
473
]
],
[
[
359,
40,
1014
],
[
1014,
24,
473
]
],
[
[
359,
63,
1512
],
[
1512,
... | [
[
[
"Chlorothiazide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Repaglinide"
]
],
[
[
"Chlorothiazide",
"{u} (Compound) causes {v} (Side Effect)",
"Pancreatitis"
],
[
"Pancreatitis",
"{u} (Side ... | Chlorothiazide (Compound) causes Pancreatitis (Side Effect) and Pancreatitis (Side Effect) is caused by Repaglinide (Compound)
Chlorothiazide (Compound) resembles Benzthiazide (Compound) and Benzthiazide may cause a moderate interaction that could exacerbate diseases when taken with Repaglinide
Chlorothiazide may cause... |
DB00647 | DB06595 | 675 | 1,491 | [
"DDInter528",
"DDInter1214"
] | Dextropropoxyphene | Midostaurin | Dextropropoxyphene is an opioid analgesic manufactured by Eli Lilly and Company. It is used in the symptomatic treatment of mild pain. It displays antitussive and local anaesthetic actions. Due to the risk of cardiac arrhythmias and overdose, possibly leading to death, dextropropoxyphene has been withdrawn from the mar... | Midostaurin (as Rydapt) is a multitarget kinase inhibitor for the treatment for adult patients with newly diagnosed acute myeloid leukemia (AML) who have a specific genetic mutation called FLT3. It was initially characterized as a potential broad-spectrum antineoplastic agent, with activity toward diverse solid and hem... | Moderate | 1 | [
[
[
675,
24,
1491
]
],
[
[
675,
23,
112
],
[
112,
23,
1491
]
],
[
[
675,
25,
888
],
[
888,
24,
1491
]
],
[
[
675,
24,
657
],
[
657,
... | [
[
[
"Dextropropoxyphene",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Midostaurin"
]
],
[
[
"Dextropropoxyphene",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazol... | Dextropropoxyphene may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Midostaurin
Dextropropoxyphene may lead to a major life threatening interaction when taken with Tamoxifen and Tam... |
DB01166 | DB11952 | 477 | 800 | [
"DDInter379",
"DDInter612"
] | Cilostazol | Duvelisib | Cilostazol is a quinolinone derivative and antiplatelet agent with vasodilating properties that has been used in the symptomatic treatment of intermittent claudication in patients with peripheral ischaemia. It is marketed under the brand name Pletal by Otsuka Pharmaceutical Co.. Cilostazol works by inhibiting both prim... | Duvelisib, also known as IPI-145 and INK-1197, is a small-molecule inhibitor of phosphoinositide-3 kinases that was designed initially to prove that simultaneous inhibition of the isoforms delta and gamma can produce a broad adaptative and innate immune cell inhibitory activity. All the work around duvelisib showed tha... | Major | 2 | [
[
[
477,
25,
800
]
],
[
[
477,
63,
222
],
[
222,
23,
800
]
],
[
[
477,
63,
300
],
[
300,
24,
800
]
],
[
[
477,
64,
11
],
[
11,
24,
... | [
[
[
"Cilostazol",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Duvelisib"
]
],
[
[
"Cilostazol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sibutramine"
],
[
"Sibutramin... | Cilostazol may cause a moderate interaction that could exacerbate diseases when taken with Sibutramine and Sibutramine may cause a minor interaction that can limit clinical effects when taken with Duvelisib
Cilostazol may cause a moderate interaction that could exacerbate diseases when taken with Letrozole and Letrozol... |
DB06186 | DB08901 | 1,439 | 1,468 | [
"DDInter969",
"DDInter1492"
] | Ipilimumab | Ponatinib | Ipilimumab is a fully humanized IgG1 monoclonal antibody that blocks cytotoxic T lymphocyte antigen-4 (CTLA-4). Blocking CTLA-4 removes an inhibitory signal from reducing the activity of T lymphocytes.[A35065,A35080,L12126] Ipilimumab was developed by Bristol-Myers Squibb and Medarex. Ipilimumab was granted FDA approva... | Ponatinib is a novel Bcr-Abl tyrosine kinase inhibitor that is especially effective against the T315I mutation for the treatment of chronic myeloid leukemia. FDA approved on December 14, 2012. | Moderate | 1 | [
[
[
1439,
24,
1468
]
],
[
[
1439,
63,
589
],
[
589,
24,
1468
]
],
[
[
1439,
24,
384
],
[
384,
63,
1468
]
],
[
[
1439,
24,
850
],
[
850,
... | [
[
[
"Ipilimumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ponatinib"
]
],
[
[
"Ipilimumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cisplatin"
],
[
... | Ipilimumab may cause a moderate interaction that could exacerbate diseases when taken with Cisplatin and Cisplatin may cause a moderate interaction that could exacerbate diseases when taken with Ponatinib
Ipilimumab may cause a moderate interaction that could exacerbate diseases when taken with Idelalisib and Idelalisi... |
DB11581 | DB11915 | 1,456 | 1,293 | [
"DDInter1926",
"DDInter1909"
] | Venetoclax | Valbenazine | Venetoclax is a BCL-2 inhibitor that was initially approved by the FDA in April 2016 [FDA label]. Proteins in the B cell CLL/lymphoma 2 (BCL-2) family are important regulators of the apoptotic (programmed cell death) process,. Venetoclax is used to treat chronic lymphocytic leukemia (CLL) and certain types of small lym... | Valbenazine is a modified metabolite of [tetrabenazine], and it is currently being approved for the treatment of various movement disorders, particularly tardive dyskinesia and chorea associated with Huntington's disease.[L47885,A261135] Tardive dyskinesia has long been regarded as a consequence of anti-dopamine recept... | Major | 2 | [
[
[
1456,
25,
1293
]
],
[
[
1456,
25,
283
],
[
283,
63,
1293
]
],
[
[
1456,
64,
392
],
[
392,
24,
1293
]
],
[
[
1456,
24,
119
],
[
119,
... | [
[
[
"Venetoclax",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Valbenazine"
]
],
[
[
"Venetoclax",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Fedratinib"
],
[
"Fedratinib",
"{u} ... | Venetoclax may lead to a major life threatening interaction when taken with Fedratinib and Fedratinib may cause a moderate interaction that could exacerbate diseases when taken with Valbenazine
Venetoclax may lead to a major life threatening interaction when taken with Lapatinib and Lapatinib may cause a moderate inter... |
DB00041 | DB00557 | 1,648 | 252 | [
"DDInter38",
"DDInter895"
] | Aldesleukin | Hydroxyzine | Aldesleukin, a lymphokine, is produced by recombinant DNA technology using a genetically engineered E. coli strain containing an analog of the human interleukin-2 gene. Genetic engineering techniques were used to modify the human IL-2 gene, and the resulting expression clone encodes a modified human interleukin-2. This... | Hydroxyzine is a first-generation histamine H<sub>1</sub>-receptor antagonist of the dephenylmethane and piperazine classes that exhibits sedative, anxiolytic, and antiemetic properties.[A1257,A187589] It was first developed in 1955, and has since remained a relatively common treatment for allergic conditions such as p... | Moderate | 1 | [
[
[
1648,
24,
252
]
],
[
[
1648,
24,
851
],
[
851,
1,
252
]
],
[
[
1648,
24,
537
],
[
537,
63,
252
]
],
[
[
1648,
24,
322
],
[
322,
... | [
[
[
"Aldesleukin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Hydroxyzine"
]
],
[
[
"Aldesleukin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nefazodone"
],
[... | Aldesleukin may cause a moderate interaction that could exacerbate diseases when taken with Nefazodone and Nefazodone (Compound) resembles Hydroxyzine (Compound)
Aldesleukin may cause a moderate interaction that could exacerbate diseases when taken with Cyclizine and Cyclizine may cause a moderate interaction that coul... |
DB01006 | DB08873 | 300 | 74 | [
"DDInter1040",
"DDInter221"
] | Letrozole | Boceprevir | Letrozole, or CGS 20267, is an oral non-steroidal type II aromatase inhibitor first described in the literature in 1990.[A190543,A1559,L11623,L11626] It is a third generation aromatase inhibitor like [exemestane] and [anastrozole], meaning it does not significantly affect cortisol, aldosterone, and thyroxine. Letrozole... | Boceprevir is a direct acting antiviral medication used as part of combination therapy to treat chronic Hepatitis C, an infectious liver disease caused by infection with Hepatitis C Virus (HCV). HCV is a single-stranded RNA virus that is categorized into nine distinct genotypes, with genotype 1 being the most common in... | Moderate | 1 | [
[
[
300,
24,
74
]
],
[
[
300,
6,
8374
],
[
8374,
45,
74
]
],
[
[
300,
21,
28769
],
[
28769,
60,
74
]
],
[
[
300,
24,
1619
],
[
1619,
... | [
[
[
"Letrozole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Boceprevir"
]
],
[
[
"Letrozole",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
... | Letrozole (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Boceprevir (Compound)
Letrozole (Compound) causes Feeling abnormal (Side Effect) and Feeling abnormal (Side Effect) is caused by Boceprevir (Compound)
Letrozole may cause a moderate interaction that could exacerbate diseases when taken with Rucapari... |
DB01577 | DB08881 | 1,529 | 868 | [
"DDInter1161",
"DDInter1925"
] | Metamfetamine | Vemurafenib | Metamfetamine (methamphetamine) is a psychostimulant and sympathomimetic drug, and a member of the amphetamine group of sympathomimetic amines. Methamphetamine can induce effects such as euphoria, increased alertness and energy, and enhanced self-esteem. It is a scheduled drug in most countries due to its high potentia... | Vemurafenib is a competitive kinase inhibitor with activity against BRAF kinase with mutations like V600E. It exerts its function by binding to the ATP-binding domain of the mutant BRAF. Vemurafenib was co-developed by Roche and Plexxikon and it obtained its FDA approval on August 17, 2011, under the company Hoffmann L... | Moderate | 1 | [
[
[
1529,
24,
868
]
],
[
[
1529,
6,
12523
],
[
12523,
45,
868
]
],
[
[
1529,
21,
28681
],
[
28681,
60,
868
]
],
[
[
1529,
63,
480
],
[
480... | [
[
[
"Metamfetamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vemurafenib"
]
],
[
[
"Metamfetamine",
"{u} (Compound) binds {v} (Gene)",
"CYP2D6"
],
[
"CYP2D6",
"{u} (Gene) is bound by {v} (Comp... | Metamfetamine (Compound) binds CYP2D6 (Gene) and CYP2D6 (Gene) is bound by Vemurafenib (Compound)
Metamfetamine (Compound) causes Hypersensitivity (Side Effect) and Hypersensitivity (Side Effect) is caused by Vemurafenib (Compound)
Metamfetamine may cause a moderate interaction that could exacerbate diseases when taken... |
DB00407 | DB05578 | 202 | 330 | [
"DDInter115",
"DDInter1566"
] | Ardeparin | Ramucirumab | Ardeparin, marketed under the US trade name Normiflo, is a low molecular weight heparin (LMWH) anticoagulant used for the prevention of postoperative venous thrombosis. Ardeparin is derived via peroxide degradation of heparin extracted from porcine intestinal mucosa. Its molecular weight ranges from 2000 to 15,000 with... | Ramucirumab is a human monoclonal antibody (IgG1) against vascular endothelial growth factor receptor 2 (VEGFR2), a type II trans-membrane tyrosine kinase receptor expressed on endothelial cells. By binding to VEGFR2, ramucirumab prevents binding of its ligands (VEGF-A, VEGF-C, and VEGF-D), thereby preventing VEGF-stim... | Major | 2 | [
[
[
202,
25,
330
]
],
[
[
202,
24,
557
],
[
557,
24,
330
]
],
[
[
202,
25,
1317
],
[
1317,
25,
330
]
],
[
[
202,
64,
1061
],
[
1061,
... | [
[
[
"Ardeparin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ramucirumab"
]
],
[
[
"Ardeparin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Deoxycholic acid"
],
[
"Deoxy... | Ardeparin may cause a moderate interaction that could exacerbate diseases when taken with Deoxycholic acid and Deoxycholic acid may cause a moderate interaction that could exacerbate diseases when taken with Ramucirumab
Ardeparin may lead to a major life threatening interaction when taken with Dipyridamole and Dipyrida... |
DB05154 | DB08912 | 740 | 1,040 | [
"DDInter1517",
"DDInter462"
] | Pretomanid | Dabrafenib | Persistent forms of tuberculosis (TB) have proven to be a major cause of global morbidity and mortality and a cause for significant concern. Research in recent years has been geared toward the development of novel therapies that target persistent forms of this disease, which have shown resistance to standard therapy re... | Dabrafenib mesylate (Tafinlar) is a reversible ATP-competitive kinase inhibitor and targets the MAPK pathway. It was approved on May 29, 2013, for the treatment of melanoma with V600E or V6000K mutation. It was also used for metastatic non-small cell lung cancer with the same mutation. In May 2018, Tafinlar (dabrafenib... | Major | 2 | [
[
[
740,
25,
1040
]
],
[
[
740,
25,
129
],
[
129,
24,
1040
]
],
[
[
740,
25,
913
],
[
913,
63,
1040
]
],
[
[
740,
24,
98
],
[
98,
63... | [
[
[
"Pretomanid",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Dabrafenib"
]
],
[
[
"Pretomanid",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Enzalutamide"
],
[
"Enzalutamide",
"{... | Pretomanid may lead to a major life threatening interaction when taken with Enzalutamide and Enzalutamide may cause a moderate interaction that could exacerbate diseases when taken with Dabrafenib
Pretomanid may lead to a major life threatening interaction when taken with Apalutamide and Apalutamide may cause a moderat... |
DB00099 | DB09074 | 440 | 1,362 | [
"DDInter735",
"DDInter1327"
] | Filgrastim | Olaparib | Filgrastim is a short-acting recombinant, non-pegylated human granulocyte colony-stimulating factor (G-CSF) analog produced by recombinant DNA technology. It has an amino acid sequence identical to endogenous G-CSF, but it is non-glycosylated unlike the endogenous G-CSF and has an N-terminal methionine added in the seq... | Olaparib is a selective and potent inhibitor of poly (ADP-ribose) polymerase (PARP) enzymes, PARP1 and PARP2.[L41100, L40908, L43792] PARP inhibitors represent a novel class of anti-cancer therapy and they work by taking advantage of a defect in DNA repair in cancer cells with BRCA mutations and inducing cell death. Ol... | Moderate | 1 | [
[
[
440,
24,
1362
]
],
[
[
440,
24,
896
],
[
896,
24,
1362
]
],
[
[
440,
24,
385
],
[
385,
63,
1362
]
],
[
[
440,
63,
491
],
[
491,
... | [
[
[
"Filgrastim",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Olaparib"
]
],
[
[
"Filgrastim",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Etoposide"
],
[
... | Filgrastim may cause a moderate interaction that could exacerbate diseases when taken with Etoposide and Etoposide may cause a moderate interaction that could exacerbate diseases when taken with Olaparib
Filgrastim may cause a moderate interaction that could exacerbate diseases when taken with Isatuximab and Isatuximab... |
DB01115 | DB08884 | 336 | 796 | [
"DDInter1291",
"DDInter800"
] | Nifedipine | Gadoxetic acid | Nifedipine, or BAY a 1040, is a first generation dihydropyridine L-type calcium channel blocker, similar to [nicardipine].[A190210,A190273,A175390,L11383] Nifedipine was developed by Bayer and first described in the literature, along with other dihydropyridines, in 1972.[A175390,A190276] Since nifedipine's development,... | Gadoxetic acid (gadoxetate) is a paramagnetic gadolinium-containing ionic linear contrast agent in which its salt form, gadoxetate disodium, is used for intravenous injection. Ethoxybenzyl diethylenetriaminepentaacetic acid is the moiety that chelates with a gadolinium ion and forms a stable complex with it to make up ... | Moderate | 1 | [
[
[
336,
24,
796
]
],
[
[
336,
6,
16319
],
[
16319,
45,
796
]
],
[
[
336,
21,
28841
],
[
28841,
60,
796
]
],
[
[
336,
1,
1081
],
[
1081,
... | [
[
[
"Nifedipine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Gadoxetic acid"
]
],
[
[
"Nifedipine",
"{u} (Compound) binds {v} (Gene)",
"ABCC3"
],
[
"ABCC3",
"{u} (Gene) is bound by {v} (Compound)... | Nifedipine (Compound) binds ABCC3 (Gene) and ABCC3 (Gene) is bound by Gadoxetic acid (Compound)
Nifedipine (Compound) causes Bronchospasm (Side Effect) and Bronchospasm (Side Effect) is caused by Gadoxetic acid (Compound)
Nifedipine (Compound) resembles Nicardipine (Compound) and Nicardipine may cause a moderate intera... |
DB00222 | DB00507 | 245 | 316 | [
"DDInter825",
"DDInter1299"
] | Glimepiride | Nitazoxanide | First introduced in 1995, glimepiride is a member of the second-generation sulfonylurea (SU) drug class used for the management of type 2 diabetes mellitus (T2DM) to improve glycemic control. Type 2 diabetes is a metabolic disorder with increasing prevalences worldwide; it is characterized by insulin resistance in acco... | Nitazoxanide belongs to the class of drugs known as _thiazolides_. Nitazoxanide (NTZ) is a broad-spectrum anti-infective drug that markedly modulates the survival, growth, and proliferation of a range of extracellular and intracellular protozoa, helminths, anaerobic and microaerophilic bacteria, in addition to viruses.... | Moderate | 1 | [
[
[
245,
24,
316
]
],
[
[
245,
24,
1171
],
[
1171,
1,
316
]
],
[
[
245,
21,
28810
],
[
28810,
60,
316
]
],
[
[
245,
24,
362
],
[
362,
... | [
[
[
"Glimepiride",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nitazoxanide"
]
],
[
[
"Glimepiride",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Meloxicam"
],
[... | Glimepiride may cause a moderate interaction that could exacerbate diseases when taken with Meloxicam and Meloxicam (Compound) resembles Nitazoxanide (Compound)
Glimepiride (Compound) causes Gastrointestinal pain (Side Effect) and Gastrointestinal pain (Side Effect) is caused by Nitazoxanide (Compound)
Glimepiride may ... |
DB00448 | DB11963 | 1,215 | 1,045 | [
"DDInter1022",
"DDInter465"
] | Lansoprazole | Dacomitinib | Lansoprazole marketed under the brand Prevacid, is a proton pump inhibitor (PPI) and is structurally classified as a substituted benzimidazole. It reduces gastric acid secretion by targeting gastric H,K-ATPase pumps and is thus effective at promoting healing in ulcerative diseases, and treating gastroesophageal reflux ... | Dacomitinib, designed as (2E)-N-16-4-(piperidin-1-yl) but-2-enamide, is an oral highly selective quinazalone part of the second-generation tyrosine kinase inhibitors which are characterized by the irreversible binding at the ATP domain of the epidermal growth factor receptor family kinase domains. Dacomitinib was devel... | Major | 2 | [
[
[
1215,
25,
1045
]
],
[
[
1215,
63,
80
],
[
80,
24,
1045
]
],
[
[
1215,
24,
187
],
[
187,
24,
1045
]
],
[
[
1215,
23,
109
],
[
109,
... | [
[
[
"Lansoprazole",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Dacomitinib"
]
],
[
[
"Lansoprazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Amphetamine"
],
[
"Amph... | Lansoprazole may cause a moderate interaction that could exacerbate diseases when taken with Amphetamine and Amphetamine may cause a moderate interaction that could exacerbate diseases when taken with Dacomitinib
Lansoprazole may cause a moderate interaction that could exacerbate diseases when taken with Pirfenidone an... |
DB00322 | DB00495 | 141 | 139 | [
"DDInter742",
"DDInter1961"
] | Floxuridine | Zidovudine | An antineoplastic antimetabolite that is metabolized to fluorouracil when administered by rapid injection. Floxuridine is available as a sterile, nonpyrogenic, lyophilized powder for reconstitution. When administered by slow, continuous, intra-arterial infusion, it is converted to floxuridine monophosphate. It has been... | A dideoxynucleoside compound in which the 3'-hydroxy group on the sugar moiety has been replaced by an azido group. This modification prevents the formation of phosphodiester linkages which are needed for the completion of nucleic acid chains. The compound is a potent inhibitor of HIV replication, acting as a chain... | Moderate | 1 | [
[
[
141,
35,
139
]
],
[
[
141,
1,
1083
],
[
1083,
24,
139
]
],
[
[
141,
1,
11230
],
[
11230,
1,
139
]
],
[
[
141,
1,
1477
],
[
1477,
... | [
[
[
"Floxuridine",
"{u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Zidovudine"
]
],
[
[
"Floxuridine",
"{u} (Compound) resembles {v} (Compound)",
"Trifluridine"
],
[
... | Floxuridine (Compound) resembles Zidovudine (Compound) and
Floxuridine (Compound) resembles Trifluridine (Compound) and Trifluridine may cause a moderate interaction that could exacerbate diseases when taken with Zidovudine
Floxuridine (Compound) resembles Idoxuridine (Compound) and Idoxuridine (Compound) resembles Zid... |
DB01362 | DB15066 | 497 | 445 | [
"DDInter960",
"DDInter821"
] | Iohexol | Givosiran | Iohexol is an effective non-ionic, water-soluble contrast agent which is used in myelography, arthrography, nephroangiography, arteriography, and other radiographic procedures. Its low systemic toxicity is the combined result of low chemotoxicity and low osmolality. | Givosiran is a small interfering RNA (siRNA) directed towards 5-aminolevulinic acid synthase, a critical enzyme in the heme biosynthesis pathway. It is manufactured by Alnylam Pharmaceuticals and was first approved for use in the United States in November 2019 for the treatment of adults with acute hepatic porphyria, a... | Major | 2 | [
[
[
497,
25,
445
]
],
[
[
497,
64,
1039
],
[
1039,
24,
445
]
],
[
[
497,
25,
1613
],
[
1613,
24,
445
]
],
[
[
497,
1,
258
],
[
258,
... | [
[
[
"Iohexol",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Givosiran"
]
],
[
[
"Iohexol",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Dexfenfluramine"
],
[
"Dexfenfluramine",
"{u... | Iohexol may lead to a major life threatening interaction when taken with Dexfenfluramine and Dexfenfluramine may cause a moderate interaction that could exacerbate diseases when taken with Givosiran
Iohexol may lead to a major life threatening interaction when taken with Peginterferon beta-1a and Peginterferon beta-1a ... |
DB01132 | DB06343 | 1,130 | 1,379 | [
"DDInter1472",
"DDInter1766"
] | Pioglitazone | Teprotumumab | Pioglitazone is an antihyperglycemic used as an adjunct to diet, exercise, and other antidiabetic medications to manage type 2 diabetes mellitus.[L11416,L11419,L11422,L11425] It is administered as a racemic mixture, though there is no pharmacologic difference between the enantiomers and they appear to interconvert _in ... | Teprotumumab is a fully human IgG1 monoclonal antibody directed against the human insulin-like growth factor-1 receptor. Following a clinical trial in which its efficacy in the treatment of thyroid eye disease (TED) was assessed, it received "breakthrough therapy" designation from the FDA in 2016 and was approved by th... | Moderate | 1 | [
[
[
1130,
24,
1379
]
],
[
[
1130,
24,
1296
],
[
1296,
63,
1379
]
],
[
[
1130,
24,
1254
],
[
1254,
24,
1379
]
],
[
[
1130,
63,
1179
],
[
11... | [
[
[
"Pioglitazone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Teprotumumab"
]
],
[
[
"Pioglitazone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Insulin degludec"
... | Pioglitazone may cause a moderate interaction that could exacerbate diseases when taken with Insulin degludec and Insulin degludec may cause a moderate interaction that could exacerbate diseases when taken with Teprotumumab
Pioglitazone may cause a moderate interaction that could exacerbate diseases when taken with Ins... |
DB00252 | DB00570 | 362 | 147 | [
"DDInter1460",
"DDInter1936"
] | Phenytoin | Vinblastine | Phenytoin is classified as a hydantoin derivative and despite its narrow therapeutic index, it is one of the most commonly used anticonvulsants.[A33595,A188832,A189219] Since it's introduction about 80 years ago, phenytoin has not only been established as an effective anti-epileptic, but has also been investigated for ... | Antitumor alkaloid isolated from Vinca rosea. (Merck, 11th ed.) | Moderate | 1 | [
[
[
362,
24,
147
]
],
[
[
362,
24,
134
],
[
134,
24,
147
]
],
[
[
362,
6,
5912
],
[
5912,
45,
147
]
],
[
[
362,
7,
6952
],
[
6952,
4... | [
[
[
"Phenytoin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vinblastine"
]
],
[
[
"Phenytoin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vinorelbine"
],
[
... | Phenytoin may cause a moderate interaction that could exacerbate diseases when taken with Vinorelbine and Vinorelbine may cause a moderate interaction that could exacerbate diseases when taken with Vinblastine
Phenytoin (Compound) binds ABCC2 (Gene) and ABCC2 (Gene) is bound by Vinblastine (Compound)
Phenytoin (Compoun... |
DB00687 | DB00872 | 870 | 1,080 | [
"DDInter747",
"DDInter438"
] | Fludrocortisone | Conivaptan | Fludrocortisone is a synthetic mineralocorticoid used in conjunction with [hydrocortisone] to replace missing endogenous corticosteroids in patients with adrenal insufficiency.[A187169,A187187] It is functionally similar to [aldosterone], the body's primary endogenous mineralocorticoid, and is structurally analogous to... | Conivaptan is a non-peptide inhibitor of antidiuretic hormone (vasopressin). It was approved in 2004 for hyponatremia (low blood sodium levels) caused by syndrome of inappropriate antidiuretic hormone (SIADH). Conivaptan inhibits both isotypes of the vasopressin receptor (V1a and V2). | Moderate | 1 | [
[
[
870,
24,
1080
]
],
[
[
870,
21,
29024
],
[
29024,
60,
1080
]
],
[
[
870,
63,
126
],
[
126,
23,
1080
]
],
[
[
870,
1,
1220
],
[
1220,
... | [
[
[
"Fludrocortisone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Conivaptan"
]
],
[
[
"Fludrocortisone",
"{u} (Compound) causes {v} (Side Effect)",
"Hypertension"
],
[
"Hypertension",
"{u} (Side... | Fludrocortisone (Compound) causes Hypertension (Side Effect) and Hypertension (Side Effect) is caused by Conivaptan (Compound)
Fludrocortisone may cause a moderate interaction that could exacerbate diseases when taken with Warfarin and Warfarin may cause a minor interaction that can limit clinical effects when taken wi... |
DB00726 | DB09082 | 1,164 | 659 | [
"DDInter1876",
"DDInter1934"
] | Trimipramine | Vilanterol | Tricyclic antidepressant similar to imipramine, but with more antihistaminic and sedative properties. | Vilanterol is a selective long-acting β2-adrenergic agonist (LABA) with inherent 24-hour activity for the once-daily treatment of COPD and asthma. This is in response to the need for longer-acting β2-adrenergic agonists to overcome poor patient compliance (due to the frequency of dosing regimens or complexities of drug... | Moderate | 1 | [
[
[
1164,
24,
659
]
],
[
[
1164,
24,
927
],
[
927,
63,
659
]
],
[
[
1164,
25,
1069
],
[
1069,
24,
659
]
],
[
[
1164,
24,
959
],
[
959,
... | [
[
[
"Trimipramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vilanterol"
]
],
[
[
"Trimipramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Encorafenib"
],
... | Trimipramine may cause a moderate interaction that could exacerbate diseases when taken with Encorafenib and Encorafenib may cause a moderate interaction that could exacerbate diseases when taken with Vilanterol
Trimipramine may lead to a major life threatening interaction when taken with Vandetanib and Vandetanib may ... |
DB00106 | DB00472 | 618 | 758 | [
"DDInter4",
"DDInter758"
] | Abarelix | Fluoxetine | Synthetic decapeptide antagonist to gonadotropin releasing hormone (GnRH). It is marketed by Praecis Pharmaceuticals as Plenaxis. Praecis announced in June 2006 that it was voluntarily withdrawing the drug from the market. | Fluoxetine is a 2nd generation antidepressant categorized as a selective serotonin reuptake inhibitor (SSRI). It gained FDA approval in 1987 and although it was initially intended for the treatment of depression, today it is commonly prescribed to manage depression in addition to various other pathologies. | Moderate | 1 | [
[
[
618,
24,
758
]
],
[
[
618,
24,
847
],
[
847,
1,
758
]
],
[
[
618,
23,
112
],
[
112,
62,
758
]
],
[
[
618,
24,
1559
],
[
1559,
63... | [
[
[
"Abarelix",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fluoxetine"
]
],
[
[
"Abarelix",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Atomoxetine"
],
[
... | Abarelix may cause a moderate interaction that could exacerbate diseases when taken with Atomoxetine and Atomoxetine (Compound) resembles Fluoxetine (Compound)
Abarelix may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can li... |
DB00054 | DB00208 | 1,432 | 1,018 | [
"DDInter6",
"DDInter1804"
] | Abciximab | Ticlopidine | Abciximab is a Fab fragment of the chimeric human-murine monoclonal antibody 7E3. Abciximab binds to the glycoprotein (GP) IIb/IIIa receptor of human platelets and inhibits platelet aggregation by preventing the binding of fibrinogen, von Willebrand factor, and other adhesive molecules. It also binds to vitronectin (αv... | Ticlopidine is an effective inhibitor of platelet aggregation. It is a prodrug that is metabolised to an active form, which blocks the ADP receptor that is involved in GPIIb/IIIa receptor activation leading to platelet aggregation. Ticlopidine is marketed under the brand name Ticlid and is indicated for patients who ca... | Major | 2 | [
[
[
1432,
25,
1018
]
],
[
[
1432,
25,
1347
],
[
1347,
64,
1018
]
],
[
[
1432,
23,
1631
],
[
1631,
62,
1018
]
],
[
[
1432,
64,
1271
],
[
12... | [
[
[
"Abciximab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ticlopidine"
]
],
[
[
"Abciximab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Clopidogrel"
],
[
"Clopidogrel",
"{u} ... | Abciximab may lead to a major life threatening interaction when taken with Clopidogrel and Clopidogrel may lead to a major life threatening interaction when taken with Ticlopidine
Abciximab may cause a minor interaction that can limit clinical effects when taken with Turmeric and Turmeric may cause a minor interaction ... |
DB01175 | DB06282 | 318 | 516 | [
"DDInter672",
"DDInter1053"
] | Escitalopram | Levocetirizine | Escitalopram is a selective serotonin re-uptake inhibitor (SSRI) and the S-enantiomer of racemic [citalopram]. It is used to restore serotonergic function in the treatment of depression and anxiety.[L8513,L8516,L8522] Escitalopram is approximately 150 times more potent than citalopram’s R-enantiomer and is responsible ... | Levocetirizine is a selective histamine H<sub>1</sub> antagonist used to treat a variety of allergic symptoms.[A181748,A181790,L7694] It is the R enantiomer of [cetirizine]. Levocetirizine has greater affinity for the histamine H<sub>1</sub> receptor than cetirizine. Levocetirizine was granted FDA approval in 1995. | Moderate | 1 | [
[
[
318,
24,
516
]
],
[
[
318,
63,
701
],
[
701,
24,
516
]
],
[
[
318,
24,
407
],
[
407,
63,
516
]
],
[
[
318,
40,
1230
],
[
1230,
2... | [
[
[
"Escitalopram",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Levocetirizine"
]
],
[
[
"Escitalopram",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clemastine"
],
... | Escitalopram may cause a moderate interaction that could exacerbate diseases when taken with Clemastine and Clemastine may cause a moderate interaction that could exacerbate diseases when taken with Levocetirizine
Escitalopram may cause a moderate interaction that could exacerbate diseases when taken with Opium and Opi... |
DB00041 | DB11817 | 1,648 | 1,259 | [
"DDInter38",
"DDInter165"
] | Aldesleukin | Baricitinib | Aldesleukin, a lymphokine, is produced by recombinant DNA technology using a genetically engineered E. coli strain containing an analog of the human interleukin-2 gene. Genetic engineering techniques were used to modify the human IL-2 gene, and the resulting expression clone encodes a modified human interleukin-2. This... | Baricitinib is a Janus kinase (JAK) inhibitor. JAKs are tyrosine protein kinases that play an important role in pro-inflammatory signaling pathways. Overactive JAKs have been implicated in autoimmune disorders, such as rheumatoid arthritis. By inhibiting the actions of JAK1 and JAK2, baricitinib attenuates JAK-mediated... | Major | 2 | [
[
[
1648,
25,
1259
]
],
[
[
1648,
24,
421
],
[
421,
24,
1259
]
],
[
[
1648,
24,
1129
],
[
1129,
63,
1259
]
],
[
[
1648,
25,
534
],
[
534,
... | [
[
[
"Aldesleukin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Baricitinib"
]
],
[
[
"Aldesleukin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Hydromorphone"
],
[
"Hydr... | Aldesleukin may cause a moderate interaction that could exacerbate diseases when taken with Hydromorphone and Hydromorphone may cause a moderate interaction that could exacerbate diseases when taken with Baricitinib
Aldesleukin may cause a moderate interaction that could exacerbate diseases when taken with Human adenov... |
DB00439 | DB08871 | 289 | 36 | [
"DDInter341",
"DDInter666"
] | Cerivastatin | Eribulin | On August 8, 2001 the U.S. Food and Drug Administration (FDA) announced that Bayer Pharmaceutical Division voluntarily withdrew Baycol from the U.S. market, due to reports of fatal rhabdomyolysis, a severe adverse reaction from this cholesterol-lowering (lipid-lowering) product. It has also been withdrawn from the Cana... | Eribulin is a microtubule inhibitor indicated for the treatment of patients with metastatic breast cancer who have previously received at least two chemotherapeutic regimens for the treatment of metastatic disease. Eribulin was isolated from the marine sponge Halichondria okadai. Eribulin is also being investigated for... | Moderate | 1 | [
[
[
289,
24,
36
]
],
[
[
289,
24,
1488
],
[
1488,
24,
36
]
],
[
[
289,
63,
168
],
[
168,
24,
36
]
],
[
[
289,
25,
609
],
[
609,
24,
... | [
[
[
"Cerivastatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Eribulin"
]
],
[
[
"Cerivastatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fludarabine"
],
[... | Cerivastatin may cause a moderate interaction that could exacerbate diseases when taken with Fludarabine and Fludarabine may cause a moderate interaction that could exacerbate diseases when taken with Eribulin
Cerivastatin may cause a moderate interaction that could exacerbate diseases when taken with Bortezomib and Bo... |
DB01011 | DB01357 | 925 | 890 | [
"DDInter1204",
"DDInter1160"
] | Metyrapone | Mestranol | An inhibitor of the enzyme steroid 11-beta-monooxygenase. It is used as a test of the feedback hypothalamic-pituitary mechanism in the diagnosis of cushing syndrome. | The 3-methyl ether of ethinyl estradiol. It must be demethylated to be biologically active. It is used as the estrogen component of many combination ORAL contraceptives. | Moderate | 1 | [
[
[
925,
24,
890
]
],
[
[
925,
63,
380
],
[
380,
40,
890
]
],
[
[
925,
63,
1438
],
[
1438,
1,
890
]
],
[
[
925,
63,
380
],
[
380,
1,... | [
[
[
"Metyrapone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mestranol"
]
],
[
[
"Metyrapone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Conjugated estrogens"
],... | Metyrapone may cause a moderate interaction that could exacerbate diseases when taken with Conjugated estrogens and Conjugated estrogens (Compound) resembles Mestranol (Compound)
Metyrapone may cause a moderate interaction that could exacerbate diseases when taken with Estradiol and Estradiol (Compound) resembles Mestr... |
DB01211 | DB01267 | 609 | 519 | [
"DDInter393",
"DDInter1381"
] | Clarithromycin | Paliperidone | Clarithromycin, a semisynthetic macrolide antibiotic derived from erythromycin, inhibits bacterial protein synthesis by binding to the bacterial 50S ribosomal subunit. Binding inhibits peptidyl transferase activity and interferes with amino acid translocation during the translation and protein assembly process. Clarith... | Paliperidone is the primary active metabolite of risperidone. The mechanism of action is unknown but it is likely to act via a similar pathway to risperidone. It has been proposed that the drug's therapeutic activity in schizophrenia is mediated through a combination of central dopamine Type 2 (D2) and serotonin Type 2... | Moderate | 1 | [
[
[
609,
24,
519
]
],
[
[
609,
63,
1664
],
[
1664,
1,
519
]
],
[
[
609,
25,
924
],
[
924,
1,
519
]
],
[
[
609,
6,
7524
],
[
7524,
45... | [
[
[
"Clarithromycin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Paliperidone"
]
],
[
[
"Clarithromycin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Risperidone"
... | Clarithromycin may cause a moderate interaction that could exacerbate diseases when taken with Risperidone and Risperidone (Compound) resembles Paliperidone (Compound)
Clarithromycin may lead to a major life threatening interaction when taken with Iloperidone and Iloperidone (Compound) resembles Paliperidone (Compound)... |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.